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ABSTRACT 
Super-porous PVA hydrogels with controlled release of IGF-1 for cartilage tissue 
engineering 
Claire E. Martin 
Advisors: Anthony M. Lowman, PhD, Kara L. Spiller, PhD 
                Guangdong Zhou, MD, PhD, Wei Liu, MD, PhD 
Repair or regeneration of articular cartilage remains one of the most difficult challenges 
in orthopedic medicine. Poly(vinyl alcohol) (PVA) hydrogels have shown promise as 
synthetic cartilage replacement materials, especially those that allow sustained release of 
insulin-like growth factor 1 (IGF-1). The goal of this study was to increase the porosity of 
the previously designed hydrogels that had an average pore size of 60 to 100µm and a 
porosity of 60 to 70%, while maintaining IGF-1 release in order to increase infiltration of 
chondrocytes from surrounding cartilage. The hydrogels were prepared using a 
previously established, single step, double emulsion technique based on a water-oil-water 
(W1/O/W2) composition. IGF-1 was encapsulated in degradable poly(lactic-co-glycolic 
acid) (PLGA) microparticles (W1/O) embedded in non-degradable poly(vinyl alcohol) 
(PVA) hydrogels (W2). The effects of processing parameters such as volume and 
composition of the water and oil phases were evaluated towards increasing hydrogel 
porosity. Hydrogels of various formulations had interconnected pores from 40 to 600um 
and average pore size of up to 337 ± 205µm, and porosities of 76% to 84%, all of which 
were increases over the previous design. The controlled release system sustained release 
of IGF-1 for 73 days in vitro, with an initial burst on the first day of 1.82 ± 1.15µg/ml. In 
order to study the controlled release of IGF-1 on cartilage tissue engineering in vivo, the 
hydrogels were seeded with chondrocytes and implanted subcutaneously into the backs of 
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nude mice and harvested after two and five weeks in vivo. The introduction of high levels 
of porosity to PVA hydrogels resulted in a reduction in mechanical properties but an 
increase in cartilage growth within the hydrogels. This study shows that the sustained 
release of IGF-1 can enhance tissue formation within the pores of a non-degradable 
hydrogel. The increase in porosity of the IGF1-eluting hydrogels may improve implant 
integration with surrounding tissue. 
 
.
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CHAPTER 1: INTRODUCTION 
Repair or regeneration of load-bearing cartilage tissue is one of the most 
challenging areas of orthopedic medicine. Cartilage tissue has a high incidence of 
damage due to sports injury or diseases such as osteoarthritis, which affects 
approximately 22% of Americans [1]. However, due to its avascularity, cartilage has a 
limited intrinsic healing ability [2]. Surgical intervention techniques used in the clinic 
include subchondral drilling, transplantation of autologous osteochondral plugs, and 
autologous chondrocyte implantation; however, these techniques have shown limited 
success in patient outcomes over the long term because of a lack of regeneration of 
healthy cartilage tissue [3]. Cartilage tissue engineering has become a prominent research 
topic in the field of regenerative medicine due to the unsatisfactory, long-term patient 
outcomes from surgical techniques [4]. These approaches have put emphasis on 
developing scaffolds to be directly implanted into a patient or to be seeded with cells, 
usually chondrocytes or mesenchymal stem cells differentiated into chondrocytes and 
subsequently implanted. Biodegradable scaffold materials can be created from natural 
and synthetic polymers including silk, collagen, elastin or poly(glycolic acid) (PGA), 
poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), 
polycaprolactone (PCL). These scaffolds have been successful in providing an 
environment for cellular in-growth and proliferation within the matrices [5]. However, 
the regenerated tissue does not provide a stiff enough structure to support the 
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physiological load found in most joints [2]. A material that better mimics the behavior 
and properties of natural cartilage is necessary. Cartilage is comprised of up to 80% of 
water, gases, metabolites, and a large amount of cations to balance negatively charged 
glycosaminoglycans (GAGs) in the extracellular matrix (ECM) [6]. Recent studies show 
that hydrogels, cross-linked polymer networks that can swell with up to 95% water, as a 
promising technology for cartilage tissue engineering due to its similar material and ECM 
formation properties to native cartilage [2, 7]. As a result of limited success with 
biodegradable scaffolds, many non-degradable synthetic polymers have been used to 
create scaffolds including poly(vinyl alcohol), polyethylene, polyurethane and 
tetrahydrofuryl methacrylate [8]. All materials have a variety of potential processing 
methods including hydrogel formation, electrospinning, freeze casting, three-dimensional 
printing, etc [9].  
Poly(vinyl alcohol) (PVA) hydrogels, in particular, have shown potential in their 
ability to provide mechanical support, swelling properties, cell migration and release of 
growth factors to facilitate mature cartilage growth in a defect [2, 10-12]. On the other 
hand, hydrogels have faced challenges with introducing large enough pores for cells to 
migrate and attach throughout the full thickness of the scaffold. Porosity has been shown 
to be critical for cell attachment and nutrient mobility [13]. Furthermore, it is imperative 
for scaffolds to have optimized porosity, as large pores allow for superior nutrient supply, 
gas diffusion and metabolic waste removal. The exact environment and porosity 
necessary for proliferation of seeded or native chondrocytes remains unknown. Research 
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has shown success in chondrocyte migration in non-degradable PVA hydrogels with 
controlled release systems of growth factors such as insulin or insulin-like growth factor I 
(IGF-1) [10, 12].  
The PVA hydrogel system has been one of the most studied hydrogel designs 
with great success in biocompatibility along with a wide variety of cross-linking options 
including consecutive freeze-thawing cycles, chemical reactions or irradiation [2, 14]. 
Additionally, PVA has excellent swelling ability, high mechanical strength, ability to 
induce a pore structure, and material longevity [14]. While PVA is a good material with 
documented ability to replicate many material properties of healthy cartilage, PVA does 
not integrate well with the surrounding tissue due its lack of cell adhesiveness, leading to 
poor ECM secretion [5]. Current research designs using PVA hydrogels have been able to 
promote cell migration as a result of porosity increases and a controlled release system. 
However, limited cell proliferation, viability, and integration with the surrounding tissue 
have been observed in these scaffolds. A strong interface is imperative to the success of a 
biomaterial in vivo. The strong interface ensures no free-moving implants in the body and 
that if used in a joint, that weight is evenly distributed, as it would be in a normal 
environment. Of the most successful studies in having a scaffold integrate into the 
surrounding tissue, chondrocytes seeded onto scaffolds with an pore diameter ranging 
from 250-500µm, produced the highest rate of cell growth and GAG secretion, which 
indicate a need for larger pores for any material to support cartilage tissue engineering 
[12, 15].  
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The aims of this work are address the following: 1) increase the porosity of PVA 
hydrogels 2) understand the protein release from the new, more porous PVA hydrogel 
and 3) evaluate the hydrogel as a cartilage tissue engineering construct. This work 
provides an understanding of the effects of porosity on protein release and the ability to 
support cartilage tissue engineering in vivo.  
CHAPTER 2: BACKGROUND  
2.1 Cartilage Biology, Structure and Function 
2.1.1 Anatomy 
Cartilage is smooth, white tissue found in many places in the body including the 
ends of bones in load-bearing joints, such as the knee and spine, the thorax, in between 
ribs, and in various tubes, such as the trachea and nose [16]. Articular cartilage the 
viscoelastic material found on the articulating bones, where it provides a frictionless 
surface for smooth joint movement. In addition to articular cartilage, the synovial fluid is 
responsible for the frictionless movement of the surfaces of the articulating joints [17].  
For example in the knee, articular cartilage is found on the bottom of the femur and on 
the top of the tibia. In between the two bones is the meniscus, a C-shaped fibrocartilage 
structure that disperses the load and friction of the knee to the tibia and femur (Figure 1). 
Cartilage is a connective tissue that is hypocellular, aneural, alymphatic, and avascular. It 
is made up of cells called chondrocytes, which are located in extracellular matrix (ECM) 
and derived from two main components: collagen and negatively-charged proteoglycans 
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[18]. Collagen II is the predominate type of collagen in the ECM. Interactions between 
fluids, proteoglycans and collagen are critical for the strong and stiff mechanical 
properties of cartilage [17]. 
There are four macrostrucutrual zones found in normal cartilage, which are the 
superficial, transitional, deep and calcified zones (Figure 2)  [19]. The superficial zone is 
the thinnest zone of articular cartilage and is comprised of flattened chondrocytes, high 
concentration of water (~80% wet weight), high collagen concentration, low 
proteoglycan content, and fibrils oriented in parallel orientation aid to the high tensile and 
shear stress. The specific organization of the superficial zone determines the mechanical 
properties of the tissue and helps in its function as a barrier for passage of large 
molecules such as antibodies from synovial fluid [17]. In the transitional zone, 
chondrocytes maintain a spherical morphology. There is a higher concentration of 
proteoglycan and the collagen fibers are arranged randomly. The majority of the dry 
weight (40-60%) of cartilage is found in this zone [19]. The deep zone also has 
chondrocytes with a spherical morphology; collagen fibrils have the largest diameter in 
this zone and are arranged in columns. The deep zone has the highest concentration of 
proteoglycans, while the density of chondrocytes remains low [18]. The calcified zone 
contains rounded chondrocytes situated in a calcified matrix where they maintain a 
hypertropic phenotype. This region is important for transition into sunchondroal bone and 
tends to act more similar to fibrocartilage, synthesizing more collagen X, than collagen II. 
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Proteoglycans are absent and the collagen fibers are arranged perpendicular to the 
articular surface  [17, 18]. 
As previously described, chondrocytes come in a variety of shapes, sizes and 
arrangement depending their location in the zones, where each zone has a highly 
organized format of ECM production and collagen, proteoglycan and fluid composition. 
Chondrocytes receive signals transmitted by the ECM, which have received mechanical 
and physiochemical signals, and affect the balance between catabolism and anabolism. 
These signals are important for the replacement of damaged matrix macromolecules [20]. 
Chemical and mechanical changes signal a cellular function and can also directly damage 
chondrocytes through nutrition alteration. Age is the major factor in the metabolic 
activity of chondrocytes and their response to signaling [21]. The tensile strength of 
weight bearing articular cartilage decreases with age, which alters the composition of the 
matrix and the activity of the chondrocytes.  
2.1.2 Cell signaling 
Chondrocytes are the only type of cell found in articular cartilage. Due to tissue 
avascularity, chondrocytes do not receive endocrine signals and therefore has a limited 
ability to repair itself. In order for chondrocytes survival, a combination of autocrine, 
paracrine and ECM signals are required. It has been shown that chondrocytes can survive 
in the absence of ECM when cultured at a high density or are provided with exogenous 
growth factors [22].  However, more generally and regularly, the function of articular 
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cartilage is dependent on the maintenance of the ECM. ECM is regulated by growth 
factors such as insulin-like growth factor 1 (IGF-1)  [23]. IGF-1 is a major anabolic factor 
in cartilage, increases the biosynthesis of proteoglycans and collagen.  It also inhibits 
ECM degradation and regulates the transcription of degradation enzymes, such as 
metalloproteinases, by up-regulating their inhibitors  [24]. IGF-1 binds to surface 
receptors, IGFRI and IGFRII, and increases the production of molecules such as collagen, 
proteoglycans and hyaluronan though signaling cascades. Several studies have shown 
that treatment of cartilage with IGF-1 leads to increased biosynthetic rates through 
increasing the concentrations of collagen, proteoglycans, and hyaluronan, therefore 
improving the ECM mechanical properties  [23]. IGF-1 also has anti-catabolic effects. 
For example, IGF-1 interferes with the signaling of interleukin-1 (IL-1), which is pro-
inflammatory and promotes ECM degradation. The effect of IGF-1 binding to a receptor 
is the up-regulation in production of interleukin receptor 2 (IL-1RII). When IL-1 binds to 
IL-1RI, a phosphorylation cascade is initiated, which has many catabolic effects. 
However, when IL-1 binds to IL-1RII, a signaling cascade is not initiated. When IGF-1 is 
introduced, it silences the inflammatory pathway of IL-1RII by competing with IL-1RI 
for IL-1  [25].  
As previously mentioned, chondrocytes respond differently to dynamic and static 
mechanical forces, where articular cartilage responds favorably to dynamic mechanical 
forces and negatively to static forces. Bonassar et al., investigated the effect of static 
compression on IGF-1 and found that the static compression altered IGF-1 action by 
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decreasing the transport speed of the growth factor through the ECM. This indicated that 
IGF-1 transport through the ECM is the rate limiting step in the synthetic response to the 
growth factor  [23].   
Another growth factor involved in differentiation of chondrocytes is transforming 
growth factor β1 (TGF-β1). TGF-β1 belongs to the TGF-β super-family of proteins and is 
expressed in various tissue specific patterns, including development and repair of 
cartilage tissue  [26]. TGF-β1 typically binds to TGF-β1 receptor 2 (TGF-β1RII), which 
transduces the signal by phosphorylating TGF-β1RI. The phosphorylation of TGF- β1RI 
initiates a cascade of the Smad family proteins. This family of proteins ends in a complex 
of Smad3 and Smad4, which is capable of translocating to the nucleus and activating 
transcription  [27]. Interestingly, the IGF-β1 related pathways have been shown to have 
some contradictory effects.  In some cases this pathway will enhance cellular 
differentiation and proliferation, while in others they have been shown to inhibit 
growth. Each of these functions have been suggested to dictate the chondrocyte’s location 
in the cell cycle [24].  
There are several factors involved in cartilage regeneration, although its presence 
is limited in vivo. One family of factors for cartilage repair is the bone morphogenetic 
protein family (BMP). BMP-7 is the most important of these factors for cartilage repair 
and has also been commonly used in cartilage tissue engineering research. The protein 
has an important role in collagen synthesis, cell proliferation, and inhibiting 
inflammatory factors. BMP-7 also maintains the chondrocyte phenotype in vitro, 
9 
 
preventing dedifferentiation or terminal differentiation, which are steps involved in 
generating fibrocartilage. Seeding BMP-7-overexpressing cells into matrices has been 
studied as a cellular and gene therapy technique for tissue. In addition to expressing ECM, 
these cells prevented fibroblast invasion, which has been shown to promote inflammation 
and degradation of tissue engineering constructs  [28]. Other methods to introduce BMP-
7 to damaged cartilage is to introduce the factor onto natural scaffolds, such as chitosan, 
or transfecting autologous chondrocytes to overexpress BMP-7 ex vivo  [29].   
2.2 Cartilage Damage 
It has been described that cartilage damage can be defined by three types of injury 
including matrix disruption, partial thickness defects and full thickness defects; which 
can also be placed into two separate categories of “direct mechanical trauma to the matrix 
without damaging cells or mechanical destruction of the cells and matrix” [18, 33]. The 
later is the more common clinically observed damage. With destruction to the matrix and 
the cells, the injury is permanent due to cartilage limited intrinsic ability to heal itself. 
Adult chondrocytes have limited migration and replication to fill in a defect. Cartilage 
injury is mainly attributed to diseases such as osteoporosis or osteoarthritis, sporting 
injury, age and standard wear and tear. More than 21%, approximately 46.4 million, of 
American adults have reported self-reported doctor-diagnosed arthritis [34]. Additionally, 
research has shown that approximately 27 million (~12% of adult population) Americans 
have osteoarthritis, resulting in an estimated economic burden of $89.1 billion annually, 
attributed to job loss, additional co-morbidity cost, etc [34, 35]. Injuries left untreated 
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result in pain, catching, clicking, locking, instability or effusions experienced by the 
patient. These symptoms can be extremely painful and debilitating for patients of all ages, 
which affect employment, sporting, and daily living activities.  
2.3 Current Surgical Techniques and Procedures for Treatment 
Current techniques used to repair cartilage include subchondral drilling, the 
transplantation of autologous osteochondral plugs, and autologous chondrocyte 
implantation (ACI) and have shown limited success in stimulating the regeneration of 
healthy cartilage tissue [2, 3]. One of the more common treatments for patients with 
cartilage defects or damage that has not reached osteoarthritis is autologous chondrocyte 
implantation (ACI). ACI is an appealing technique because the patients own cells are 
isolated from a non-load-bearing area of the joint and cultured in vitro for 4-6 weeks and 
then injected into the original defect site and sealed with a periosteal flab, regenerating 
hyaline-like cartilage. Currently, there is only one Food and Drug Administration (FDA) 
approved product, which is manufactured by Genzyme Corporation, called Carticel  [36]. 
Carticel is indicated for use in young patients who have had repeated trauma to the 
femoral condyle and have had limited success with arthroscopic, microfracture, abrasion 
or osteochondral grafting techniques  [36]. Clinically, this product has shown success in 
long-term patient outcomes in a study of 72 patients, with 69% of patients showing 
excellent outcomes and 17% resulting in failure or diminished function, pain, etc. Of the 
17% failure, the failure was determined within three years after the ACI. These results 
indicate that ACI is a viable solution for patients who are not diagnosed with 
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osteoarthritis (as use in osteoarthritic patients is a contraindication). However, the 
procedure and Carticel requires the use in conjunction with debridement and two overall 
surgeries, with the double surgery time being a major drawback in patient cost and 
hospital overhead  [37]. 
Many of these techniques remain the current standard of care in the US, with no 
current treatment or therapy for patients with osteoarthritis. Ultimately, there remains an 
unmet need for a long-solution for patients who are diagnosed with osteoarthritis or 
severe joint pain or require reconstruction that minimizes operating time and provides 
mechanical and integrative support.   
2.4 Cartilage Tissue Engineering 
2.4.1 Biodegradable scaffolds 
Biodegradable scaffolds comprised of naturally derived or synthetic polymers, 
have shown promise in supporting the proliferation and cartilage tissue [2, 3]. These 
technologies are designed to promote regeneration and completely replace the missing 
tissue. These materials are commonly categorized into three different derivatives of 
synthetically based, carbohydrate-based, and protein-based. Synthetically-based materials 
are comprised of polyesters such as poly(lactic acid), poly(glycolic acid), 
polycaprolactone, and co-polymer, carbohydrate-based materials are commonly created 
out of alginate, chitosan, or hyaluronan. Additionally scaffolds can be created out of 
protein-based materials such a collage and fibrin. Combinations of these categories are 
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often explored to improve various parameters such as mechanical strength, cell 
attachment or porosity. These materials have a wide range of processing parameters in 
order to fabricate scaffolds including electrospinning, solvent casting, porogen leaching, 
gas foaming, fiber mesh or bonding, and freeze drying [38]. 
2.4.2 Hydrogels 
Natural polymer scaffolds tend to have improved cell adhesion and infiltration 
mainly due to their macromolecular properties that are similar to native ECM. The types 
of materials that have been utilized to develop hydrogels include collagen, silk alginate, 
agarose, and hyaluronic acid  [5, 39]. These naturally-derived hydrogel scaffolds promote 
an excellent environment for chondrogenesis, but their construction can be difficult to 
manipulate and enhance even with the addition of various chemical cross-linkers or 
degradable synthetic polymers [14]. Hydrogels made of purely synthetic materials have 
allowed better control over structure and material properties such as swelling, mechanical 
strength, porosity, and crosslinking density  [40]. 
One study conducted by Chao et al., highlights two technologies using silk as the 
major structural component; one a silk hydrogel and the other a porous silk scaffold, both 
formulated using a salt-leaching technique  [41]. The silk hydrogel and scaffold were 
seeded using bovine chondrocytes. These samples were subsequently tested in vitro for 
GAG content, compressive modulus, overall DNA content and histological analysis at 
days 0, 14, 28, and 42. It was observed that the silk hydrogel and porous scaffold both 
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supported cellular ingrowth in vitro. Glycosaminoglycan and DNA content both saw 
significant increases over time, with compressive modulus at its maximum on day 42. 
Intrinsic biomechanical testing of equilibrium and dynamic modulus were also performed 
on the silk constructs.  
2.5 Poly(vinyl alcohol) (PVA) Hydrogels 
In vivo studies with implanting PVA hydrogels alone have had minimal success 
due to limited integration with cartilage [5, 11]. The lack of success is likely because 
PVA is a hydrophilic polymer, preventing chondrogenesis and attachment throughout the 
scaffold, which inhibits the cells from producing new ECM within the scaffold  [42]. 
While PVA alone has not provided a good solution, the introduction of degradable 
particles, often poly(lactic-co-glycolic acid) (PLGA), whether loaded with a drug, growth 
factors or genes, have shown promise in creating an implant with integrative properties 
while maintaining superior mechanical strength  [2, 43]. 
One US Company, Carticept Medical, Inc., manufactures the Cartiva Synthetic 
Cartilage Implant (SCI). This implant is a PVA cryogel that is implanted into a pre-
drilled hole with a similar technique used for osteochondral autograft or allograft 
transplantation. Currently, clinical trials are being completed in Canada and the United 
Kingdom; sales and distribution of the product are only approved in international markets  
[44]. While PVA hydrogels have shown great potential and success, the major 
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disadvantage of this design is the implant’s inability to fully degrade and become a part 
of the body. 
2.6 Controlled Release of Growth Factors 
The controlled release of growth factors such as IGF-1, transforming growth 
factor beta (TGF-β) and bone morphogenic protein II (BMP-7) from a hydrogel have 
been shown to stimulate chondrocytes from the surrounding cartilage to migrate into the 
implant and integrate the implant with the surrounding tissue [43]. While growth factors 
have addressed integration with some success, limited chondrocyte migration from the 
defect is another aspect of poor integration[2, 5].  
The incorporation of TGF-β has been used in tissue engineering applications in 
order to control the differentiation of chondrocytes, and to prevent re-differentiation into 
hypertrophic chondrocytes or osteoblasts.  Chou et al., studied the use of TGF-β1 in a tri-
co-polymer sponge scaffold made up of gelatin, chondroitin-6-sulfate and hyaluronic acid 
[45], in an effort to mimic the natural ECM. The scaffold was conjugated with TGF-β1 to 
increase chondrocyte proliferation and up-regulate ECM expression of type II collagen 
and glycosaminoglycans (GAG). The TGF-β1 caused an up-regulation of the tissue 
inhibitor metalloproteinases (TIMPs), which prevented the ECM from degradation. The 
researchers found that scaffolds with immobilized TGF-β1 released the growth factor 
continuously into the medium, which up-regulated parathyroid hormone related peptide 
(PTHrP), which is involved with chondrocyte maturation. The up-regulation of PTHrP 
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inhibited chondrocytes from differentiating into hypertrophic chondrocytes or osteoblasts, 
which is a large challenge in cartilage engineering.  Researchers concluded that the tri-co-
polymer scaffold provided a successful environment for chondrocyte growth. 
Additionally, that the introduction of TGF-β1 into the scaffold promoted cartilage-like 
expression relative to ECM components, and prevented the re-differentiation of the 
chondrocytes  [45].  
As previously described, IGF-1 and TGF-β1 have been shown to promote 
differentiation and maintenance of the chondrocyte phenotype in tissue engineering 
research. The two growth factors have been studied combination, due to their success 
separately, in order to enhance chondrocyte growth and differentiation.  Davies et al. 
aimed to understand and improve chondrocyte amplification, while preventing de-
differentiation into osteoblasts or hypertrophic chondrocytes  [24].  The research 
primarily focused on understanding the specific effects of IGF-1 and TGF-β1 on mature 
adult chondrocytes. This was done by first understanding how the two growth factors 
function separately and together to enhance the biosynthesis of collagen and 
proteoglycans [24]. It was hypothesized that IGF-1 and TGF-β1 have important roles in 
tissue homeostasis. Researchers investigated the effects of introducing the growth factor 
on receptor expression and endogenous growth factor expression, and subsequently how 
the ECM development was affected. Davies et al. found that IGF-1 was more effective 
than TGF-β1 in promoting functional collagen expression; however, collagen was 
detected in the culture medium of chondrocytes treated with TGF-β1  [24]. All this 
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suggested that there were significant differences in the post-translational processing of 
collagen depending on how the translation was triggered or which growth factor began 
the pathway. Furthermore, there was also a hypothesized difference in the cross-linking 
of the polymers formed after each different translation pathway.  It was observed that 
collagen formed in the presence of TGF-β1 when more cross-links were present, whereas 
the cross-linking levels of collagen were not affected by the presence of IGF-1.  Adding 
TGF-β1 to cells alone had little to no effect on the endogenous expression. Conversely, 
IGF-1 alone had inhibitory effects on the endogenous expression.  When both factors 
were used together, TGF-β1 mRNA was suppressed and IGF-1 mRNA increased, which 
suggested an initial increase in biosynthesis due to the introduction of the growth factors.  
The initial increase was then followed by a decrease, which may have been a result of the 
short half-lives of IGF-1 and TGF-β1. Researchers also hypothesized a threshold after 
which exogenous growth factors will stimulate or inhibit receptor expression based on the 
amount of growth factor incorporated. The researchers concluded that mature 
chondrocytes have a response to IGF-1 and TGF-β1, together, which increased cellular 
proliferation and biosynthesis of GAG and collagen.  Additionally IGF-1 and TGF-β1 
cause direct changes in ECM composition, which can be specifically mediated by 
regulating the amounts of exogenous and endogenous factors  [24].   
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Figure 1 – Schematic of the knee joint showing articular cartilage [46]. 
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Figure 2 – Schematic of the four macrostructure zones of cartilage [18].  
 
 
  
19 
 
CHAPTER 3: ENGINEERING DESIGN & RESEARCH GOALS 
Recent studies performed by Spiller et al. incorporated a degradable mesh of PGA 
surrounding a porous, IGF-1 eluting PVA hydrogel to enhance cell migration, attachment 
and implant integration with surrounding tissue. The PVA hydrogel was proposed for 
direct implantation into a defect to provide immediate mechanical stability, while the 
degradable PGA mesh fibers aimed to provide an optimal porosity and cell attachment 
environment to promote implant integration with surrounding tissue. Furthermore, the 
IGF-1 releasing from the PVA hydrogel aimed to enhance cartilage tissue formation 
within the entire PGA/PVA scaffold. The study illustrated how the controlled release of 
IGF-1 significantly enhanced cartilage formation in vivo when the scaffolds were seeded 
with chondrocytes and subsequently implanted subcutaneously in nude mice for six 
weeks. Cartilage formed in place of the PGA fibers had the potential to promote 
integration with surrounding tissues, but chondrogenesis was only observed at the edges 
of the PVA hydrogel. It was suspected that the cartilage cells formed only where the PGA 
mesh was placed without migrating into the PVA hydrogel, due to small pore size and 
lack of pore interconnectivity. The hydrogels could not be seeded directly with 
chondrocytes because of low levels of cell attachment and poor seeding efficiency. 
Enhancing the static cell seeding method and subsequent seeding efficiency, while 
maintaining the controlled release of IGF-1, would allow cells to be seeded directly onto 
the PVA hydrogel without the use of the PGA fibers. Increased porosity would also 
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increase cell seeding efficiency while providing a superior architecture for cartilage 
growth. 
Herein lies a need for a more porous hydrogel of similar design that can provide 
immediate mechanical stability upon implantation and that also promotes cell migration, 
attachment and implant integration with surrounding tissue. Due to the preliminary 
success of the previously designed hydrogel, this work sought to improve the design by 
increasing the porosity, average pore size and cell seeding efficiency, while maintaining 
material composition and the controlled release system of IGF-1. The same analyses of 
the new and previously designed hydrogel would allow a direct comparison of the two 
and better understand the role porosity and cell seeding efficiency can play in promoting 
direct cell attachment to a very hydrophilic material.  
Several methods for increasing the porosity of hydrogels were investigated 
including salt leaching, increasing the volume of organic solvent used in the PLGA 
solution, varying the PVA concentration, and varying stir time, speed, and technique. 
Pore size and overall porosity were confirmed with environmental scanning electron 
microscopy (ESEM) in conjunction with image analysis software, ImageJ, and micro 
computed topography (µCT). In addition to evaluating the hydrogel porosity, the swelling 
behavior was evaluated by obtaining dry and wet weights after being immersed in 
phosphate buffered saline (PBS). Characterizing the swelling behavior of a PVA 
hydrogel in PBS provided a baseline comparison to the previous design and also indicates 
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porosity due to changes in swelling behavior. After confirming that the pore structure and 
hydrogel behavior was improved over the previous design, the hydrogels were loaded 
with IGF-1 to ensure the controlled release system was maintained. Different processing 
parameters for protein loading were investigated to ensure efficiency in loading and also 
that microparticles remained homogenously distributed throughout the PVA hydrogel 
during manufacture. Subsequently, characterization of the IGF-1 release profile was 
conducted using enzyme-linked immunosorbent assay (ELISA) and cell-based bioactivity 
assays in order to determine if the new hydrogel design had good potential to support 
cells in vivo.  
The new design was characterized for cell seeding efficiency to determine the 
optimal method for retaining cells on a highly porous and hydrophilic material in vitro.  
Finally, the constructs’ viability as a cartilage tissue engineering scaffold was evaluated 
in vivo in a subcutaneous implantation model. 
 
Discussed in detail in subsequent chapters, the specific aims of this work are: 
1. Increase the porosity of PVA hydrogel while maintaining sustained release 
of IGF-1. 
2. Increase cell seeding efficiency of PVA hydrogel and evaluate tissue 
engineering potential in vivo. 
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CHAPTER 4: INCREASING POROSITY OF PVA HYDROGEL WHILE 
MAINTAINING SUSTAINED RELEASE OF IGF-1 
Part 1 - Increasing porosity of PVA hydrogel 
4.1 Introduction 
In order to ensure a successful re-design of the hydrogel, pore size and porosity 
criteria have been set. Pore sizes must be larger than a chondrocyte (10-30µm), but also 
within a range of previously successful pore sizes. In previous hydrogels created with 
gelatin, PVA and other scaffold materials, pore sizes ranging from 50-250µm yielded 
successful cell adhesion and tissue engineering within the materials’ pores [10, 12, 15]. 
Additionally, another important parameter to consider in tandem with average pore size is 
overall percent porosity. Previous studies that correspond to the optimal average pore size 
suggest an average porosity of 50% or greater  [15, 47]. As previously described, this 
section aims to explore a variety of techniques to improve overall pore size and porosity 
of the PVA hydrogels. 
Salt leaching is one form of porogen leaching, which is an established method for 
introducing pores into polymer scaffolds. This method works by introducing an inorganic 
porogen (i.e. sodium chloride) that remains insoluble in the organic compounds 
commonly used to fabricate scaffolds. The salts’ insolubility allows them to be later 
leached out using water, which does not affect a degradable or non-degradable polymer 
used to create hydrogels  [48]. This technique is particularly useful in a laboratory setting 
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because only a small amount of polymer is necessary for fabrication, whereas other 
methods (i.e. extrusion or spinning machines) for introducing high porosity require large 
amounts of polymer  [48]. This method has successfully generated large pores in 
scaffolds derived from polymers such as PLGA, PVA, chitosan, polyothoesters, acrylic 
ethyl acrylate, etc  [49]. Additionally, while salt leaching was previously deemed 
unsuitable for incorporating growth factor release  [50], dexamethasone was successfully 
introduced in the polymer phase of PLGA scaffolds, with large pores fabricated from a 
gas foaming/salt leaching method  [51]. Furthermore, a similar method was used for 
sustained release of angiogenic growth factors such as β-fibroblast growth factor (bFGF) 
and heparin  [52]. Park et al. demonstrated the ability to introduce a sustained release 
system, while using salt leaching as a means to introduce interconnected pores with sizes 
ranging from 300-500µm, through subsequent soaking of activated heparin and bFGF 
solutions  [53]. Salt leaching showed success in creating pores in PLGA, as well as in 
chitosan-PVA scaffolds. Because of Wang et al.’s success with salt leaching in a 
composite chitosan-PVA material, there was a good likelihood that large pores within a 
PVA hydrogel may have potential to be fabricated using a salt leaching technique  [54]. 
In addition to salt leaching for increasing porosity, other mixing variations can be used to 
introduce air for pore introduction. Vortexing and overhead mixing for longer periods of 
time have been shown to increase overall porosity of scaffold materials. Previous studies 
have shown what to initially increase with increased stirring speed  [55]. These 
techniques also marry very closely; porosity can be affected by varying stirring time in a 
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salt leaching method  [56]. Additionally, overhead stirring time and vortexing are good 
ways to generate a more homogenously distributed pore structure  [57]. 
Salt leaching with overhead mixing had documented success in generating pores 
as large as 300-500um and porosity up to 90%, which has been shown to be most 
effective for chondrocyte migration and proliferation within a scaffold  [48]. Lee et al., 
showed that gelatin scaffolds salt leached with 40-50% salt/gelatin weight ratios 
exhibited adequate mechanical strength and ability to support fibroblast growth and 
proliferation within the scaffold after two weeks  [58]. Due to the success of previous 
studies with chitosan-PVA scaffolds, gelatin, and PLGA, it was suggested that salt 
leaching could be attempted with PVA alone. 
4.2 Methods 
4.2.1 Methods for increasing PVA hydrogel porosity 
4.2.1.1 Salt leaching technique used in conjunction with suspension method for 
microparticle incorporation 
 A 10% or 15% solution of PVA (99% hydrolyzed, MW 99,000, Sigma-Aldrich) 
and poly(vinyl pyrrolidone) (PVP, MW 40,000, Sigma-Aldrich) in the ratio of 99:1 
PVA:PVP for stability was created in water  [47]. To control the size of pores formed 
using salt leaching, sea salt crystals were either ground with a mortar and pestle or left 
unground. Salt crystals were added to the PVA hydrogel solution at weight ratios of 
44.4%, 26.7%, 13.3%, 8.3%, and 6.7% in 15% PVA, and 20% in 10% PVA. The initial 
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weight ratio of 44.4% was used as the baseline weight ratio, which was between the 
specified range of successful salt leaching for optimal pore size, porosity and support of 
cell migration and proliferation [58]. Salt was added to the PVA solution with an 
overhead mixer or manually stirred for times ranging from one minute to ten minutes; 
during the salt mixing stage, 1.8ml of water was added to simulate the addition of drug 
loaded microparticles. Afterwards, solution was poured or manually pushed into a 15ml 
centrifuge tube and frozen in a -20°C freezer and subject to seven freeze thaw cycles of 
21 hours of freezing at -20°C and 3 hours of thawing at room temperature before slicing 
into cylindrical hydrogels. A schematic of the manufacturing process is shown in Figure 
3. Salt was leached from the samples by soaking in deionized water at room temperature 
for one week, replacing the water 2-3 times per day.  
4.2.1.2 Single step process for hydrogel fabrication, varying water-oil-water parameters 
for increased porosity 
Hydrogels with an initial dry composition of 60wt% PLGA microparticles loaded 
with IGF-1 and varying weight ratios of PVA were prepared in a single step using a 
modification of previously described methods of a double emulsion technique as seen in 
Figure 4 [10]. 60wt% PLGA was selected to maintain the similar drug delivery design as 
the previously evaluated materials, which allowed for appropriate drug loading and 
distribution of microparticles throughout the hydrogel, and direct comparison to the 
previous design as per the design constraints. The primary emulsion, phosphate-buffered 
saline (PBS) was added to an organic phase of 50:50 PLGA (DLG 2A, MW: 19,000, 
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Lakeshore Biomaterials, SurModics Pharmaceuticals, Birmingham, AL) in 
dichloromethane (DCM, Sigma-Aldrich). This emulsion was stirred for 30 minutes and 
then added dropwise to 15%, 10% or 7% solutions of PVA (99% hydrolyzed, MW 
99,000, Sigma-Aldrich) and poly(vinyl pyrrolidone) (PVP, MW 40,000, Sigma-Aldrich), 
in the ratio of 99:1 PVA:PVP, in water. Concentrations of DCM were varied to determine 
the best concentration for the optimal porosity (pores 200µm or larger) and were 
compared with previously characterized methods for the hydrogels as tissue engineering 
scaffolds [11]. The emulsion was stirred or vortexed for varying times, poured into 15ml 
centrifuge tubes, and flash frozen in an acetone/dry ice bath, before being exposed to six 
cycles of freezing at -20°C for 21 hours and thawing at room temperature for three hours. 
The hydrogels were then sliced into cylinders that were approximately 15mm in diameter 
and 1-3mm in height, dehydrated through an ethanol series, and dried by critical point 
drying. Immediate observations of success were made by visually confirming the absence 
of complete separation of dichloromethane and hydrogel solution during freeze thaw 
cycles, and also for the presence of visible pores after slicing. 
4.2.2 Characterization of hydrogel structure with ESEM and µCT 
Dry hydrogels (n=3), each about 15mg, were immersed in phosphate-buffered 
saline (PBS) at 37°C for four days and then analyzed using wet mode environmental 
scanning electron microscopy (ESEM, Model: FEI/Phillips XL30), at an accelerating 
voltage of 20kV, so that the hydrogels could be imaged in their hydrated state. ImageJ, 
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image analysis software developed by and available for free from the US National 
Institutes of Health, was utilized to measure the pore diameter of each ESEM image  [59]. 
Additionally, dry hydrogel samples were analyzed using micro-computed tomography 
(µCT, Model: Skyscan 1172, Kontich, Belgium) (n=3). The resolution was 2.9µm and 
the x-ray source was 61kV. The data were reconstructed using cone-beam reconstruction 
software (Nrecon, Skyscan). Three hundred images per sample were segmented into 
binary images using greyscale values (15-30). These images were used to build a 3-D 
virtual model and to determine porosity based on volume of a 1mm x 1mm x 0.9mm 
representative portion (CTAnalyzer, Skyscan). Average pore size was determined by 
measuring the diameters of all of the pores in five binarized images per sample. 
4.2.3 Characterization of swelling behavior of hydrogels 
4.2.3.1 Swelling in PBS 
The swelling behavior of the 60 wt% 55 vol% DCM in 7% PVA hydrogels were 
analyzed by immersing pre-weighed, critical-point dried samples (n=4) from each batch 
(n=4) in PBS, which was changed every 2-3 days and maintained at 37°C. Samples were 
subsequently weighed after three days and one week of swelling in PBS. The swelling 
ratio, Q, was calculated by the ratio of the swollen hydrogel mass to the dry hydrogel 
mass. 
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4.3 Results & Analysis 
4.3.1 Salt leaching for pore introduction 
4.3.1.1 Effects of salt to PVA ratio 
Salt leaching is an extensively characterized method for introducing pores into 
biomaterial scaffolds due to its simple, reproducible history in generating a wide range of 
pore sizes and porosities  [60]. The 44.4% weight ratio of grinded sea salt to PVA (salt-
PVA) yielded a very stiff and stable hydrogel albeit difficult to manipulate due to high 
viscosity of the solution. Additionally, the water added to simulate the addition of 
microparticles appeared to sink during freezing, suggesting unsuccessful suspension of 
the microparticles in the PVA. To improve handling ability and mixing, salt content was 
reduced to weight ratios of 26.7%. The solution was chunkier than the 44.4% weight ratio 
solution and required manual stirring, suggesting that the salt content was too high. The 
solution yielded a similarly stiff and stable hydrogel compared to the 44.4% weight ratio 
solution, but had large air pockets that produced large holes throughout the hydrogel 
rather than pores. The large air pockets were thought to come from the chunkiness of the 
solution and the pushing of the very viscous solution into the 15ml centrifuge tube. 
Similar to the 44% weight ratio solution, the water added to simulate microparticles sunk 
in the 26.7% solution.  
Reducing the PVA concentration from 15% to 10% was attempted to increase 
handling ability and decrease solution viscosity. The resultant solution was thick with 
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homogenous air bubbles; however no undissolved salt crystals were visible. Water 
simulating microparticles sunk to the bottom of the centrifuge tube. Resultant hydrogels 
had a freeze pattern with little to no visible pores or pore structure. 
Generally, for the samples with a higher weight ratio (26.7% and 44.4%) of salt-
PVA, the salt crystals sank immediately to the bottom, suggesting heterogeneous 
distribution of pores. Furthermore, the samples with weight ratios of greater than 10% 
had enough salt, but were generally challenging to handle, mix and resulted in hydrogel 
with large air pockets and limited pore structure from the salt leaching. Therefore, higher 
weight ratios of salt-PVA were no longer used due to poor handle ability and lack of pore 
structure formation.  
4.3.1.2 Effects of various stirring methods with low weight ratios of salt-PVA 
Due to high viscosity of 44% and 26.7% salt-PVA solution a lower weight ratio 
of salt-PVA of 13.3% with decreased stirring time was attempted to increase handling 
ability and decrease solution viscosity for improved freezing and pore formation. The 
resultant solution had flowable viscosity and had visible salt crystals throughout. 
Hydrogels were stiff and stable, had visible pores and retained the added water simulating 
microparticles. Large holes were also observed in the gels, suggesting the manual stirring 
introduced too much air. Lower weight ratios of salt-PVA were attempted to provide a 
less viscous and pourable solution. 
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Lower weight ratios of grinded salt-to-PVA were attempted at 8.3% and 6.7% 
using the overhead mixer; each of the weight ratios yielded milky, cloudy and thick 
solutions that poured easily into 15ml centrifuge tubes without the addition of too much 
air. Salt crystals were not visible in the resultant hydrogels, and pore size and visible pore 
structure was minimal. Water added to simulate microparticles did not sink in these 
hydrogels. Upon further visual inspection, the salt began to dissolve within one minute of 
overhead stirring in the PVA; salt crystal size became uniform, suggesting that overall 
salt crystal size and subsequently porosity was directly affected by stirring method and 
time. 
4.3.1.3 Effect of stirring time and salt crystal preparation/size 
A repetition of the 6.7% salt-PVA weight ratio was attempted with ungrinded salt 
and manual stirring to determine if the less rigorous stirring method as compared to 
overhead stirring, had any visual affect on salt crystal size or resultant porosity during the 
manufacturing process. Larger, ungrinded, salt crystals with reduced stirring time of 
approximately one minute yielded a solution with uniform, visible salt crystals during 
manufacture. Although the proportions of salt to PVA of 7% or less (6.7%) worked well, 
in that the water did not sink in the centrifuge tube, these samples had little to no pores 
during slicing and soaking. Ultimately, there was not enough salt in the samples with 
weight ratios of salt to PVA of 10% or less to create a porous hydrogel. 
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Despite leaching out the salt for one week at room temperature, while changing 
the water 2-3 per day, resultant hydrogels with larger or ungrinded sea salt crystals did 
not produce any pore structure. Additionally, hydrogels created with a higher weight ratio 
of salt-to-PVA with grinded sea salt also did not produce any pores within the PVA 
hydrogels. A summary of all observations made during the manufacture, hydrogel slicing 
and leaching is shown in Table 1. The lack of porosity was mainly attributed to the 
majority of the salt crystals being chopped up or dissolving too quickly during stir time. 
Furthermore, during salt grinding variation in size was inevitable, which led to 
heterogeneity of salt distribution throughout the solution. The larger crystals were too 
large and tended to attract and grab on to the smaller crystals making the salt deposits in 
the gels too large to be leached out and to leave an ideal pore. With the proportions of salt 
being generally low in tandem with overhead or manual mixing techniques, the 
freeze/thaw cycles likely further dissolved any residual salt, leaving minimal pores 
behind. Smaller salt crystals would have been too small to leave the ideal pore size, and 
likely dissolved into even smaller sizes during the freeze thaw cycles.  
Ultimately, salt did not adequately leach out of the hydrogels over the duration of 
soaking. Hydrogels that had some salt leaching did not yield sufficiently large or 
interconnected pores to continue using the method. In conclusion, the salt-leaching 
method was deemed inadequate for the set of criteria and constraints. The technique did 
not provide adequate pore size, porosity and structure to provide an ideal environment for 
cell migration and proliferation within the non-degradable PVA hydrogel. 
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4.3.2 Increased organic solvent for pore introduction 
A double emulsion technique was employed for the previous design and method 
for fabricating the PVA hydrogels  [61]. In order to directly compare to the previous 
design, the same design composition and similar manufacturing techniques were used. 
The PLGA microparticles were directly incorporated into the PVA in a water-oil-water 
(W1/O/W2) fashion; by increasing the volume of DCM (O), the PVA (W2) will have more 
organic solvent to crosslink around, creating more void-space after the solvent is 
extracted out of the hydrogels post-manufacture  [47]. Increasing the organic phase in 
hydrogel manufacture has been shown to increase pore size, porosity and 
interconnectivity of pores  [62]. Furthermore, to combat the challenges associated with 
maintaining homogenous distribution of the organic solvent in the mixture prior to flash 
freezing, longer and faster stirring times were employed. This method combines the 
positive results that showed increasing the amount of organic solvent increased porosity 
and increased stirring time can also introduce high porosity  [47, 57].  
4.3.2.1 Increased organic solvent yielded increased porosity, but poor repeatability 
Solvent casting, as this method is commonly referred to, has been shown to 
provide good control over pore size and general porosity  [63]. Increasing the organic 
solvent (O phase) from the previous design’s 35% volume of DCM, was the first attempt 
to increase porosity in the hydrogels [2]. By fixing the initial design’s dry polymer mass 
at 60 wt% PLGA and 40% PVA and subsequently increasing the organic solvent content, 
the correlation between porosity, interconnectivity of pores and general ease of 
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manufacture with increasing organic solvent volume were understood. An increase from 
35 vol% of DCM to 55 vol% with 60wt% PLGA in 10% PVA resulted in complete phase 
separation after flash freezing; the DCM sunk to the bottom of the tubes (Figure 5). This 
suggested that the mixing method during the manufacture of the hydrogels was not 
adequate to appropriately homogenize the emulsion. Manual stirring or agitation of the 
emulsion jars was first attempt to homogenously mix the emulsion, which resulted in 
hydrogels with little to no sinking of DCM and had large, homogenously distributed, 
visible pores during slicing and solvent leaching.  
Due to the apparent success of 55 vol% with 60 wt% PLGA in 10% PVA, it 
suggested that perhaps even more porosity could be introduced with a higher volume of 
organic solvent.  Using the same method of increased stir time and manual stirring in 
addition to the stir bar in the final emulsion-stirring phase just prior to flash freezing, a 
formulation comprising 60 vol% DCM with 60 wt% PLGA in 10% PVA was attempted. 
The even further increased organic solvent emulsion resulted in hydrogels that were 
visibly more porous than the previous 55 vol% with 60% wt% PLGA in 10% PVA. The 
successfully produced hydrogels with 60 vol% DCM, 60 wt% PLGA in 10% PVA were 
initially characterized using µCT and ESEM by analyzing the average pore size of one 
sample. The percent porosity was calculated to be 76%, which was an increase over the 
previous studies with similar composition (60 wt%, 35% vol in 10% PVA), which was 
found to have an approximate porosity of 63%  [61, 64].  
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When attempting to repeat the hydrogel batches created with 55 vol% or 60 vol% 
DCM, all samples failed to replicate the previous results where no DCM sank. Because of 
the repeated lack of success with 55 vol%, the 60 vol% was abandoned. New stirring 
techniques were attempted with the 55 vol% emulsions to attempt to replicate the 
porosity including lengthened stir time, vortexing, allowing the DCM to evaporate, and 
more frequent manual stirring. Vortexing was the least successful method with most 
DCM sinking, while manual stirring with extended stirring time, increasing from 10 
minutes to 40 minutes, yielded more homogenous emulsions that tended to flash freeze 
well and keep microparticles and organic solvent suspended throughout the freeze 
thawing cycles. In addition to lengthened stir time the emulsion was stirred uncovered, 
allowing the DCM to evaporate off, resulting in hydrogels that were porous, albeit not as 
visibly porous as the previously successful 55 vol% hydrogels. Perhaps allowing the 
DCM to evaporate may in fact help in producing a hydrogel with good porosity without 
DCM sinking. During the extended stirring time, it was observed that at 30 minutes the 
emulsion became white and thick, as opposed to the previously used 10 minutes, 
indicating this amount of time was needed to ensure homogeneity and appropriate mixing 
to prevent phase separation during flash freezing or freeze thaw cycles.  The 30 minute 
stirring time was combined with the manual stirring throughout the whole manufacture 
with 55 vol% and 60 vol% to determine if the new techniques had any effect on 
repeatability. However, all samples yielded hydrogel batches with sunken DCM. A 
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summary of all observations made during the manufacture and hydrogel slicing is shown 
in Table 2. 
Repeatability remained one of the largest challenges with increasing the organic 
solvent concentration in the overall hydrogel manufacturing. Many of the repeated 
batches resulted in sunken DCM and likely the protein loaded microparticles along with 
it. Despite the sunken organic solvent, the repeated batches underwent the same freeze 
thaw cycling, which revealed similar visual porosity that was observed in samples with 
successful organic solvent suspension. This suggests that highly porous materials can be 
created by increasing the volume of organic solvent, but may lack the ability to 
homogenously suspend protein-loaded microparticles without employing additional 
mixing techniques to ensure homogeneity during initial freezing and subsequent freeze 
thaw cycles. There appears to be a saturation point where the volume of organic solvent 
is too high, where the organic solvent cannot be encapsulated regardless of dry polymer 
weight from the PLGA microparticles or PVA. However, currently there is not a 
definitive value or volume of organic solvent that has been shown to be the cut-off where 
hydrogels formulations with PVA & PLGA are no longer able to suspend the 
microparticles within the PVA hydrogel homogenously. Without the microparticles 
deposited homogenously, the theoretical protein loading and drug release have the 
potential to yield heterogeneous results. With the one-time success of a hydrogel batch 
created with 60 wt% PLGA, 55 vol% DCM in 10% PVA and the previous design’s 
hydrogels created with 60 wt% PLGA, 35 vol% in 10% PVA collectively suggest a 
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volume of DCM between 35% and 55% will be the threshold for creating high porosity 
while maintaining homogenous microparticle suspension. 
Mixing techniques and duration were found to be crucial to the success of the 
hydrogel mixture during freezing. More specifically, the stirring of the final emulsion for 
10 minutes or less did not yield homogenous mixtures or successful hydrogels. Faster and 
more aggressive manual stirring and agitation throughout the duration of final emulsion 
(in addition to the stir bar), provided a more homogenous mixture that had a tendency to 
remain emulsified longer than without the additional stirring time. The stir bar did not 
likely circulate the emulsion properly, as the oil phase of the primary emulsion had a 
tendency to float on the top of the mixture without being completely mixed in. With the 
additional manual mixing, the protein-PLGA emulsion was recirculated within the 
hydrogel solution for more homogenous distribution of protein. 
In conclusion, increasing the organic solvent during the hydrogel manufacture 
resulted in an increase in porosity and pore interconnectivity. Furthermore, increasing the 
organic solvent reduced the reproducibility of homogenous microparticle suspension 
throughout the hydrogels, but was not found to considerably reduce porosity or pore size.  
4.3.3 Varying dry polymer mass for increased porosity 
By reducing the dry mass of the PVA, the second aqueous phase (W2), there 
would be less overall mass in the hydrogel allowing larger pores to form during the 
double emulsion manufacturing process. In a study with poly(acrylic acid), researchers 
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found that polymer content was very critical in porosity; higher polymer content has been 
associated with smaller average pore diameters. Therefore, by decreasing the polymer 
content, the overall porosity will increase  [62]. Lower and higher concentrations of PVA 
were attempted, as lower concentrations would yield more pores, while a higher 
concentration would provide a more mechanically stiff hydrogel, which are both 
important for cartilage tissue engineering. Varying the dry polymer mass would provide 
further understanding of polymer content and its effects with increased organic solvent. 
4.3.3.1 Increasing polymer dry mass yielded unsuccessful suspension of microparticles 
 In an effort to maintain the high porosity observed in the samples with 55 vol%, 
but potentially provide a more mechanically stiff and repeatable hydrogel design, the dry 
mass of PVA was increased from 10% to 15%. This experiment was used to determine if 
porosity could be maintained while increasing hydrogel crystallinity and stability that is 
important for long-term biomedical use  [65]. The double emulsion did not have the 
similar cloudy and frothy appearance as did the emulsions created with 10% PVA. The 
emulsion was more opaque with a slightly clumpy, less homogenous appearance than the 
emulsions created with 10% PVA. Hydrogel manufacture was unsuccessful yielding a 
large amount of DCM sunken similar to that seen in Figure 5.  
As polymer concentration increases there is less amount of water present in the 
hydrogel solution, which usually results in thicker pore walls, leading to enhanced 
stability and stiffness of the polymer network. While increasing the PVA concentration 
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may have led to increased stiffness, the emulsion was not successfully mixed and resulted 
in poor suspension of microparticles within the polymer matrix. Despite the addition of 
the primary emulsion into the 15% PVA solution, the PVA solution remained intact and 
was not broken up by the primary emulsion, as was observed when using the 10% PVA. 
Literature suggests that stirring speed and intensity is important to break up the oil phase 
during microparticle formation [66]; however, additional manual mixing of the primary 
and secondary emulsions did not adequately break up the viscous 15% PVA solution. 
With the final emulsion not appropriately mixed, the phase separation between the 
primary emulsion and the PVA solution occurred more quickly leading to the sunken 
DCM. In conclusion, the concentration of PVA was not increased in order to maintain 
porosity and reproducibility. 
4.3.3.2 Decreasing polymer dry mass yielded successful and repeatable suspension of 
microparticles 
Hydrogels created with 60 wt% PGLA, 55 vol% DCM in 7% PVA were 
successfully produced and initially characterized by analyzing the average pore size of a 
representative sample and the percent porosity was calculated to be 84%, nearly 10% 
higher than the previously successful design of 60 vol% DCM, 60 wt% PLGA in 10% 
PVA at 76% porosity, and 20% higher than the design characterized in Spiller et al. [2]. 
ESEM was performed to observe the hydrogel pore structure and ensure uniform 
microparticle distribution. Microparticles were dispersed throughout the hydrogels 
(arrows, Figure 6A-E). A low magnification image of a less porous space on the hydrogel 
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reveals a large density of microparticles (Figure 6A). ImageJ analysis of ESEM images 
revealed an average pore size of 337 ± 205µm, with pores ranging from 50-600µm in 
diameter. Large pores evenly distributed throughout the hydrogel had interconnectivity 
through mostly small pores approximately 40-60µm as seen in the upper left-hand corner 
of Figure 6F. Pore structure was also confirmed with µCT where pore size and 
interconnectivity were similar to that found in the ESEM images (Figure 7).  
With the challenges of repeatability faced by the previously successful design of 
60 wt% PLGA, 55 vol% in 10% PVA, one approach to stabilize the manufacturing 
process was to further reduce the amount of polymer present in the external aqueous 
phase. The main concept behind lowering the polymer concentration for increased 
porosity is that with more water present in the PVA solution, more water droplets can 
coalesce with each other to create interconnected water channels and consequently more 
pores  [66]. Furthermore, with the increased amount of water present in the hydrogel 
solution there is more freezable water contained in the manufacturing process that is later 
removed during the ethanol series  [67]. Thus, leaving behind more pores and suggesting 
a lower concentration of PVA may lead to more pores.  
The PVA concentration was lowered from 10% to 7%, while holding constant the 
60 wt% PLGA and 55 vol% of DCM. The final emulsion was stirred for 30 minutes and 
manually agitated every 3-5 minutes, which yielded a solution more opaque than 
previous batches. The hydrogel batch did not appear to have any DCM sink and resulted 
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in very porous hydrogels. The resultant hydrogels were weak and flimsy upon gross 
qualitative observations, which was confirmed in literature where it was stated that 
decreasing the concentration of PVA resulted in decreases in hydrogel stiffness  [68]. The 
pore size and structure from the 60 wt%, 55 vol% in 7% PVA visually appeared to have 
the largest pores out of all of the samples created. A summary of all observations made 
during the manufacture and hydrogel slicing is shown in Table 3. 
Large pores were confirmed with µCT and ESEM of hydrogels fabricated with 60 
wt% 55 vol% in 7% PVA with a porosity of 84% (n=1), which was an improvement from 
the same hydrogels prepared with 10% PVA (Figure 6 & Figure 7). In conclusion, the 
average pore size of 337 ± 205µm, with pore size ranging from 50-600µm, provided an 
excellent match with the required specified pore size of 50-250µm ranging up to 500µm. 
With the specifications met for porosity, the hydrogel design had high potential to 
support chondrogenesis and as a tissue engineering scaffold.  
4.3.4 Swelling studies yielded similar behavior as previous design 
Swelling studies conducted in PBS are commonly used to gain a preliminary 
understanding of hydrogel and potential degradation behavior in aqueous conditions. In 
addition to using PBS, DMEM is another alternative. Swelling studies are often 
conducted in DMEM to simulate in vitro cell culture conditions. Furthermore, another 
medium which has more recently been used is an osmotically controlled polyethylene 
glycol (PEG), which has been shown to more closely mimic the environment present in 
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vivo. Joint or in vivo environments are vastly different due to proteins present, osmotic 
pressure, and chemical interactions in the body  [61]. 
4.3.4.1 Swelling studies in PBS 
Swelling studies were performed on hydrogel samples created with 60 wt% 
PLGA, 55 vol% in 7% PVA. The hydrogels were analyzed for swelling behavior in PBS 
in order to gain a preliminary understanding of changing hydrogel properties in terms of 
degradation and general swelling behavior. After three days in PBS, the hydrogels had a 
swelling ratio of 6.39 ± 0.44, and after one week the swelling ratio increased to 7.07 ± 
0.63 (Figure 8). Swelling in PBS showed swelling ratios of 6.4 – 7.1 after only one week, 
which was higher than the approximate 2.8 observed at one week in the previous design 
created by Spiller et al.  [61, 64], further indicating increased porosity. Chondrogenesis 
has been shown to be best supported with scaffolds of a swelling capacity, or ratio, of 6-8, 
which suggested that the hydrogel design would better support cartilage tissue 
engineering during the first week  [32].  
The swelling behavior of the previous hydrogel design with microparticles, by 
Spiller et al., produced a slight increase in porosity over four weeks when swollen in PBS  
[61]. These results were also confirmed with the swelling ratio, Q, where there was a 
slight decrease after one week in PBS but subsequently increased every week afterwards 
(Figure 9). While a short-term preliminary study was performed, the new hydrogel 
formulation doubled the swelling ratio observed in the previous study. Literature states 
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that the swelling ratio and porosity are directly related when swelling in PBS over time, 
confirmed by Spiller et al.’s work  [64, 69]. Therefore, similar to the swelling ratio, the 
new formulation of hydrogel is expected to have an approximate two-fold increase in 
porosity. In conclusion, the swelling behavior of the new hydrogel formulation was 
significantly improved over the previous design indicating similar increases in porosity as 
well. 
4.3.5 New hydrogel formulation was successfully loaded with IGF-1 
With the optimal pore size, structure and manufacturing method developed, 
testing of actual drug loading into the microparticles was the next crucial step to ensure 
the hydrogels would still yield the same porous, reproducible performance. The previous 
design developed by Spiller et al. utilized the double emulsion technique for drug loading. 
Therefore, in order to directly compare the two studies, the same manufacturing 
processes were maintained [2]. IGF-1 was combined with acetic acid and BSA to give the 
appropriate pH and protection of the protein, respectively  [70]. It was found that the 
method was not repeatable when the protein IGF-1 was loaded into the hydrogel batch 
using acetic acid and BSA. The organic solvent did not remain suspended during the 
initial freezing and during subsequent freeze thaw cycles, even though the same hydrogel 
was previously and successfully created using blank microparticles. Therefore, it was 
suspected that interaction with acetic acid caused the poor outcomes. 
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Acetic acid is commonly used to aid in the encapsulation of drugs that have low 
solubility’s in neutral pH, but it also to precipitate the PLGA to physically form the 
microparticles  [71, 72]. Acetic acid has also been shown as an organic solvent 
replacement for DCM  [71], which suggests that the addition of acetic acid during the 
internal aqueous phase did not aid in the formation of microparticles, but rather added to 
the volume of organic solvent to further cause the DCM to sink and risk of microparticles 
sinking as well. In the case of loading IGF-1 into the PLGA microparticles, the acetic 
acid was strategic in that IGF-1 is most soluble in pH below 5.0 with the ability to create 
solutions up to 500mg/ml  [72]. However, because of the need to only create a solution of 
1mg/ml, a neutral pH was acceptable. This allowed the internal aqueous phase to only be 
comprised of IGF-1 and BSA. Even with the removal of acetic acid from the 
manufacturing process, the hydrogels created from 60 wt% PLGA, 55 vol% DCM in 7% 
PVA were not repeatable, suggesting that the organic solvent volume was simply too 
high. Hydrogels created with 60 wt% PLGA, 45 vol% DCM in 7% PVA resulted in 
repeatable and porous hydrogels; hydrogel composition and details are highlighted in 
yellow on Table 3. A representative hydrogel sample had interconnected pores with an 
average pore size of 191 ±112µm, with a range of pore sizes of approximately 40µm to 
400µm as calculated from ESEM images using ImageJ software. During the slicing and 
solvent leaching, the hydrogel pores were visible upon inspection (Figure 10). PLGA 
microparticles were formed in the PVA hydrogels, where the hydrogel solution acted as 
the external aqueous phase. Interconnected pores were present throughout the structure, 
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with microparticles homogenously dispersed throughout the hydrogels (Figure 11, 
arrows). In conclusion, the final hydrogel formulation of 60 wt% PLGA, 45 vol% DCM 
in 7% PVA produced porous hydrogels with successfully suspended IGF-1 loaded 
microparticles within the polymer matrix.     
4.4 Conclusions 
Increasing the volume of organic solvent in the oil phase and decreasing the 
concentration of PVA resulted in high porosity that was better than the previous design, 
while other methods such as salt leaching, did not yield pores within the PVA hydrogel. 
However, there was an observed threshold for which the volume of organic solvent used 
to create the microparticles became too high. Nonetheless, despite the organic phase and 
likely the microparticles along with it sinking during the manufacturing of the hydrogels, 
pores were still observed in resultant hydrogels. This suggests that the increase in organic 
solvent can be used for increasing porosity but investigation of advanced mixing methods 
would be required to ensure homogenous microparticle suspension throughout the 
hydrogel. The hydrogel formulation that was chosen to move on to the next aim were 
those prepared with 60wt% PLGA, 45vol% DCM, and 7% PVA. Importantly, these 
hydrogels had the same PLGA/PVA composition as previous designs but with increased 
porosity, allowing analysis of the effects of porosity on drug release and support of 
cartilage tissue engineering.  
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Part 2 – Maintenance of sustained release of IGF-1 
4.5 Introduction 
While IGF-1 eluting PVA hydrogels have been extensively characterized, the new 
hydrogel formulation from 60wt% PLGA, 45 vol% DCM in 7%, had not been previously 
attempted or characterized. Prior to working with cells or implanting a material in vivo, it 
is imperative to understand the effects of the material in vitro. In addition to the new 
hydrogel formulation, two other processing parameters were altered that may have 
affected the drug loading efficiency and the overall release profile of the protein. 
 During the manufacturing of the previous design’s hydrogel, a high molecular 
weight of PLGA (MW: 65,000) was used for create the microparticles, while in the new 
hydrogel the microparticles are created from a lower molecular weight PLGA (MW: 
19,000) in an effort to introduce more pores sooner through the faster degradation of the 
lower molecular weight PLGA. In the previous design, acetic acid was used in the 
internal aqueous phase to precipitate the polymer for the formation of microparticles and 
also to bring the pH low enough to efficiently solubilize the IGF-1; no acetic acid was 
used in the new hydrogel formulation, as the microparticles formed without acetic acid 
and the concentration of IGF-1 loaded was so small that the protein was adequately 
soluble at a neutral pH. Prior to testing the new hydrogel with cells or implanting the 
material in vivo, in vitro release profile characterization was performed using enzyme-
linked immunosorbent assay (ELISA).  
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ELISA is a very commonly used assay to detect the release of proteins or drugs 
from microspheres alone, or from drug eluting materials. This assay has been very 
successful in monitoring the release of IGF-1 from various types of hydrogels such as 
hydrogel composites created from Type I collagen, chondroitin sulfate, a thermosensitive 
copolymer based on N-isopropylacrylamide, acrylic acid, N-acryloxysuccinimide and a 
macromer poly(trimethylene carbonate)-hydroxyethyl methacrylate, polyethylene oxide-
based, gelatin, PVA and others  [2, 73-75]. While some research has detected IGF-1 
concentrations over short periods of time, sustained release of IGF-1 over longer periods 
of time, for example up to 46 days, has been shown to enhance cartilage healing when 
localized  [2, 5, 64]. Because IGF-1 is involved in the development of many tissues and 
regulates signaling of many cells, localization is important to ensure the protein does not 
adversely affect other tissues and cells  [76].  In addition to analyzing the release profile 
of a protein eluting hydrogel, assessment of the bioactivity of an encapsulated protein, is 
necessary. Quantifying the release profile and bioactivity of a drug-eluting scaffold 
provides appropriate basis for in vitro cell or in vivo studies  [77]. 
In this work, the controlled release of IGF-1 from the hydrogel created from 60 
wt% PLGA, 45 vol% DCM in 7% PVA was characterized in vitro, until experimental 
hydrogel samples released protein concentrations that were no longer different from the 
blank hydrogels. Additionally, a cell-based proliferation assay was conducted to 
determine if the encapsulated protein remained bioactive during the release. 
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4.6 Methods 
4.6.1 Preparation of IGF-1 eluting, porous PVA hydrogels 
Hydrogels with an initial dry composition of 60wt% PLGA microparticles loaded 
with IGF-1 were prepared in a single step using a modification of previously described 
methods of a double emulsion technique [10]. Recombinant human IGF-1 (Peprotech, 
Rocky Hill, NJ) was dissolved in phosphate buffered saline (PBS) and 0.1% bovine 
serum albumin (Sigma Aldrich, St. Louis, MO) at concentrations of 0µg/ml and 
333µg/ml. The IGF-1 solution was added to an organic phase of 50:50 PLGA (DLG 2A, 
MW: 19,000, Lakeshore Biomaterials, SurModics Pharmaceuticals, Birmingham, AL) in 
dichloromethane (DCM) (Sigma-Aldrich). This emulsion was stirred for 30 minutes and 
then added dropwise to a 7% solution of PVA (99% hydrolyzed, MW 99,000, Sigma-
Aldrich) and poly(vinyl pyrrolidone) (PVP, MW 40,000, Sigma-Aldrich),  in the ratio of 
99:1 PVA:PVP, in water, so that the volume of DCM was 45 vol% of the entire mixture. 
These concentrations were based on previously characterized methods for the hydrogels 
as tissue engineering scaffold [11]. This emulsion was stirred for 30 minutes with manual 
agitation every 3-5 minutes, poured into tubes, and frozen in an acetone/dry ice bath, 
before being exposed to six cycles of freezing at -20°C for 21 hours and thawing at room 
temperature for 3 hours. The hydrogels were then sliced into cylinders that were 
approximately 15mm in diameter and 1.25mm in height, dehydrated through an ethanol 
series, and dried by critical point drying.  
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4.6.2 Characterization of IGF-1 loading and release 
Hydrogels loaded with IGF-1 were characterized in vitro to obtain the release 
profile; hydrogels (n=3) of 0µg/ml and 333µg/ml dose were immersed in 2ml PBS and 
penicillin/streptomycin in a shaking waterbath at 37°C. The release medium was replaced 
with fresh medium every two days for 73 days. Samples were analyzed for concentration 
of IGF-1 using an enzyme-linked immunosorbent assay (ELISA, R&D Systems, 
Minneapolis, MN).  
4.6.3 Characterization of IGF-1 bioactivity 
To quantify IGF-I bioactivity an MCF-7 cell proliferation assay was adapted from 
R&D Systems (Minneapolis, MN)  [78]. Due to limited bioassay resolution, samples of 
released protein were analyzed for the first two weeks. Accordingly, release samples 
were diluted to 80ng/ml in PBS, which were compared against IGF-I standards at the 
same concentration. MCF-7 cells were washed three times and resuspended in serum-free 
media (DMEM/F12; 10µg/ml transferrin; 0.2% BSA) at a density of 100,000cells/ml. 
Using a 96-well plate, 50µl of bioassay serum-free media, 25µl of IGF-I standard or 
sample, and 50µl of cell suspension were added to each well. Plates were incubated for 
four days at 37°C and 5% CO2. Wells with no cells or no IGF-I served as negative 
controls. Following incubation 25µl of Cell Titer-Blue (Promega, Madison, WI) was 
added to each well and incubated for an additional 4 hours at 37°C and 5% CO2. Sample 
fluorescence was recorded at 560Ex/590Em. All samples were run in triplicate with n=3.  
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4.7 Results & Analysis 
4.7.1 Sustained release of IGF-1 from hydrogels 
Release of IGF-1 from the hydrogels was detected over 73 days. The release study 
was terminated when the IGF-1 release was no longer significantly different than the 
control. The theoretical protein loading was calculated using the equation below: 
333µg IGF1  1.75g (hydrogel dry mass/batch)  x 0.015g  (avg. hydrogel mass)hydrogel = 2.854µg IGF1hydrogel  
Equation 1 - Theoretical protein loading calculation 
IGF-1 released from the hydrogel on the first day with a burst of 1.82 ± 1.15µg, which 
was 63.8 ± 40.3% of the theoretical protein loading (Figure 12). The theoretical protein 
loaded is representative of the IGF-1 loaded into the hydrogel batch rather than directly 
into the PLGA microparticles.  During the addition of protein to the internal aqueous 
phase, the entire concentration of drug loaded was not completely encapsulated with 
100% efficiency (Equation 1). IGF-1 continued to release at a constant rate from day 17 
to day 55 at approximately 12ng/day, tapering off to approximately 1ng/day from day 57 
to day 73. At day 73, the total cumulative released averaged to 2.981 ± 1.232µg/hydrogel. 
The high standard deviation observed in the average overall cumulative release is due to 
two of the three samples releasing significantly more IGF-1 than was theoretically loaded 
(3.928µg/hydrogel and 3.428µg/hydrogel). This suggests that the IGF-1 was 
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heterogeneously dispersed during manufacturing of the hydrogels. Heterogeneous IGF-1 
in the hydrogels yielded a variable IGF-1 release shown mainly during the first 11 days 
of release, as seen with the high error found on day 1.  
The controlled release of IGF-1 from the newly designed PVA hydrogels yielded 
a very similar cumulative release profile as the low dose of approximately 
3.3µg/hydrogel from Spiller et al. [2]. However, the new hydrogel design had a very 
large initial burst of IGF-1 observed on the first day of the release study, which 
corresponds to an average concentration that is over 60% of the theoretical IGF-1 loaded 
into the hydrogel. This was significantly different than the previous design, which 
released approximately 2.6% of the theoretical IGF-1 loaded into the hydrogel on the first 
day [2]. 
The large initial burst of the new design as compared to the previous design can 
be explained with the decrease in molecular weight of PLGA (19kDa) used to fabricated 
the microparticles embedded in the PVA hydrogel. The lower molecular weight polymer 
is more soluble in the organic solvent creating microporous microparticles  [79, 80]. 
Lower molecular weight polymers, which are more soluble in organic solvent than their 
higher molecular weight counterparts, also yield smaller microparticles, which creates 
more surface area for drug diffusion to occur. Larger micropores in the microparticle 
morphology lead to protein escape through cracks and pores during fabrication, which 
may have led to the more voluminous burst release in vitro [79]. Additionally, the 
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increased porosity and swelling behavior is another major factor in the release profile and 
subsequently the large burst observed on the first day. The new hydrogel’s average pore 
size of approximately 200µm was significantly larger than the hydrodynamic radius of 
IGF-1, which dictates the release mechanism of diffusion and bulk degradation  [81]. 
Therefore, with increased porosity there is more surface area for the release medium to 
surround the microparticles leading to a faster and large burst release. Another factor that 
could be attributed with the increase in overall protein release is the decrease in PVA 
concentration. A previous study found that decreasing PVA concentration increased the 
percentage of drug release (dexamethasone) from PLGA nanoparticles in a PVA 
hydrogel  [82]. 
Embedding microparticles in hydrogels has been shown to temper the release of 
IGF-1 over time, which may explain why the release of IGF-1 was sustained twice as 
long as the previous design  [2, 81]. After Day 73, the release study revealed the samples 
cumulatively released 2.981µg/hydrogel, which was slightly higher than the theoretical 
dosing of 2.854µg/hydrogel. This data suggests that there was heterogeneity of the IGF-1 
dosage between samples, likely resulting from slow encapsulation of IGF-1 during the 
manufacture process (Figure 13).  
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4.7.2 Bioactivity encapsulated IGF-1 
IGF-1 release on day 1 to day 11 increased MCF-7 cellular proliferation 
significantly compared to negative controls without IGF-1 (Figure 14). The extent of 
MCF-7 proliferation was not significantly different between IGF-1 released from 
hydrogels and freshly prepared solutions of IGF-1, indicating that IGF-1 remained 
bioactive over time. The success of the bioactivity assay in conjunction with the release 
from ELISA indicates that ELISA can successfully establish the concentration of an 
encapsulated bioactive protein [2]. The concentrations of release protein were only high 
enough for detection by the assay for the first 11 days of release, but it is likely that the 
protein was still active for a longer period of time. Furthermore, the bioactivity of the 
MCF-7 cells have been shown to exhibit dose-dependent increase in proliferation in the 
presence of IGF-1, which is very similar to chondrocytes response to IGF-1, making the 
commercially available cell line an ideal platform for bioactivity testing  [83]. The 
bioactivity of the protein over time is imperative in its function to enhance localized cell 
proliferation and differentiation, as the systematic administration of growth factors, 
without the protection a controlled release system delivers, is often unpredictable, 
unstable, and can result in potential dose-dependent carcinogenicity  [84]. In conclusion, 
the bioactivity of the new hydrogel design was sustained for the first 11 days in vitro, 
suggesting the release of IGF-1 would support cartilage formation in vivo. 
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4.8 Conclusions 
The release of IGF-1 from the newly designed, more porous PVA hydrogel was 
sustained for 73 days. The controlled release of the new design was sustained for twice as 
long as the previous design’s, which was loaded with a slightly higher dose and released 
for a total of 32 days [2]. However, due to the increase in porosity and decrease in 
molecular weight of PLGA used to fabricate the microparticles, a large initial burst was 
observed on the first day. Additionally, the highly porous hydrogels cumulatively 
released over 100% of the theoretical drug loading, which suggests heterogeneous IGF-1 
loading and release likely in response to increased porosity. While the release of IGF-1 
was heterogeneous in vitro, the good bioactivity and high porosity of the hydrogel 
suggest potential to support cartilage tissue engineering in vivo. 
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Figure 3 – Manufacturing schematic of the salt leaching technique where the 
microparticles and salt were suspended in the polymer hydrogel in a two-step process. 
Salt crystals were to be leached out in a third subsequent step.  
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Figure 4 – The previously established, novel, double emulsion technique, titled the 
“direct incorporation” method that was employed in one step to introduce high levels of 
porosity while suspending microparticles throughout the hydrogel [2]. 
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Table 1: List of manufacturing parameters and observations during manufacture, 
slicing and leaching for samples created using the salt leaching technique. *water was 
used to simulate the addition of drug-loaded microparticles. 
PVA NaCl/PVA (wt/wt) Water* Stirring 
Observations During 
Manufacture 
Observation During 
Slicing and Leaching 
15% 44.4 1.8ml 
5 minutes 
overhead 
mixer, 
manual 
During overhead stirring, 
salt-PVA solution became 
too viscous to be stirred. 
Solution was stuck on 
mixer blade was manually 
stirred and pushed into 
centrifuge tube. 
Gel was stiff and stable 
enough to be sliced 
without freezing. Water 
sunk to the bottom of 
centrifuge tube. 
15% 26.7 1.8ml 
8 minutes 
overhead 
mixer, 
manual 
After the 8 minute stir, the 
salt-PVA solution became 
semi-flowable and very 
viscous. Solution became 
stuck on mixer blade and 
was manually stirred and 
pushed into centrifuge tube. 
Gel was stiff and stable 
enough to be sliced 
without freezing. Water 
sunk to the bottom of 
centrifuge tube. Large air 
pockets throughout gel 
(0.5-1mm) 
15% 13.3 1.0ml 1 minute manual 
Salt crystals remained 
intact. Homogenous air 
bubbles observed. 
Salt crystals were visible 
and intact in hydrogels. 
Large pores/holes were 
observed. Water did not 
sink to the bottom of 
centrifuge tube 
15% 8.3 1.8ml 1 minute manual 
Salt crystals remained 
intact. Homogenous air 
bubbles observed. 
Salt crystals were visible 
and intact in hydrogels. 
Large pores/holes were 
observed. Water did not 
sink to the bottom of 
centrifuge tube 
15% 6.7 1.8ml 
10 
minutes 
overhead 
mixer 
After 5 minutes of stirring, 
the salt-PVA solutions 
became milky and thick. 
Poured into centrifuge tube. 
Salt crystals were not 
visible. 
Sample had minimal 
visible pores. Multiple 
air pockets existed 
within samples. Water 
did not sink to bottom of 
centrifuge tube 
15% 6.7 1.8ml 
2 minutes 
overhead 
mixer 
Salt was ungrinded sea salt. 
After 2 minutes of stirring, 
the solution began to cloud 
and thicken. Salt crystals 
appeared more visible. Lots 
of air bubbles. 
Samples were slightly 
stiffer than samples with 
longer stirring time. 
Water did not sink to 
bottom of centrifuge 
tube 
10% 20 1.8ml 
10 
minutes 
overhead 
mixer 
Solution was thick, but 
flowable. Air bubbles were 
visible, but salt crystals 
were not. 
Water sunk to bottom of 
centrifuge tube. 
Hydrogels had a freeze 
pattern with no visible 
pore structure 
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Table 2 - List of manufacturing parameters and observations made with increased 
volume percentage of organic solvent using the double emulsion technique. All 
samples were created with 60 wt% PLGA.  
PVA DCM (vol%) 
Int. .Aq 
Phase 
Comp. 
Final Emulsion Stirring 
Parameters 
Observations during 
Freezing 
Observations during 
Slicing 
10% 55 PBS 10 minutes, stir bar. Covered. DCM sank. - 
10% 60 PBS 10 minutes, stir bar. Covered. DCM sank. - 
10% 55 PBS 
10 minutes, stir bar. Manual 
agitation prior to pouring 
for flash freezing. Covered. 
Emulsion appeared 
homogenous; no 
sunken DCM. 
Visibly porous. 
10% 60 PBS 
10 minutes, stir bar. Manual 
agitation prior to pouring 
for flash freezing. Covered. 
Emulsion appeared 
homogenous; no 
sunken DCM. 
Visibly porous. Samples 
were slightly more 
porous than the gels 
created with 55 vol%. 
10% 65 PBS 
10 minutes, stir bar. Manual 
agitation prior to pouring 
for flash freezing. Covered. 
DCM sank. - 
15% 55 PBS 
10 minutes, stir bar. Manual 
agitation prior to pouring 
for flash freezing. Covered. 
Emulsion was not as 
cloudy or frothy as 
solutions created in 
10% PVA; solution 
was opaque and 
slightly clumpy. DCM 
sank 
- 
10% 55 PBS Vortex, 10 seconds. 
Emulsion appeared 
white and frothy after 
10 seconds. DCM sank 
- 
10% 55 PBS 40 minutes, stir bar. Uncovered. 
Emulsion became 
thick and white after 
~30 minutes of 
stirring. Solvent likely 
evaporated. 
Samples were less 
porous than the gels 
created with 55 vol%. 
Visibly porous. 
10% 60 PBS 
20 minute, stir bar at 
350rpm. Manual agitation 
every 3-5 minutes. 
Covered. 
DCM sank. - 
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Table 3 - List of manufacturing parameters and observations made with decreased 
overall polymer mass using the double emulsion technique. All samples were created 
with 60 wt% PLGA. Bolded and highlighted yellow selections were the final designs. 
PVA DCM (vol%) 
Int. .Aq 
Phase 
Comp. 
Final Emulsion 
Stirring Parameters 
Observations during 
Freezing 
Observations during 
Slicing 
7% 55 PBS 30 minutes, stir bar. Covered. 
Emulsion was more 
opaque and runny than 
samples created with 10% 
PVA. 
Visibly porous, but 
appeared more flimsy prior 
to cutting and during 
soaking. 
7% 55 PBS 
30 minute, stir bar. 
Manual agitation 
every 3-5 minutes. 
Covered. 
Emulsion appeared 
homogenous and opaque; 
no sunken DCM. 
Samples appeared to be 
porous with homogenous 
pores. Gels cut at 1.25mm 
thickness had the good 
pores, with no pores going 
directly through the 
hydrogel. 
7% 55 
10mM 
acetic 
acid, DI 
water, 
0.1% BSA 
15-18 minute, stir 
bar. Manual agitation 
every 3-5 minutes. 
Pre-froze 7% PVA in 
conical part of 
centrifuge tube. 
Covered. 
Emulsion was 
homogenous during 
freezing. After first freeze 
thaw cycle, the 7% PVA 
in the conical region of the 
centrifuge tube did not 
crosslink. DCM sank. 
- 
7% 55 
IGF-1, 
10mM 
acetic 
acid, DI 
water, 
0.1% BSA 
30 minute, stir bar. 
Manual agitation 
every 3-5 minutes. 
Covered. 
Emulsion was 
homogenous during 
freezing. DCM sank after 
first freeze thaw cycle. 
- 
7% 55 
IGF-1, 
PBS, 
0.1% BSA 
30 minute, stir bar. 
Manual agitation 
every 3-5 minutes. 
Covered. 
Emulsion was 
homogenous during 
freezing. DCM sank after 
first freeze thaw cycle. 
- 
7% 55 PBS, 0.1% BSA 
30 minute, stir bar. 
Manual agitation 
every 3-5 minutes. 
Covered. 
Emulsion was 
homogenous during 
freezing. DCM sank after 
first freeze thaw cycle. 
Visibly porous; however 
drug distribution is 
unknown due to sunken 
DCM. 
7% 45 PBS 
30 minute, stir bar. 
Manual agitation 
every 3-5 minutes. 
Covered. 
Emulsion appeared 
homogenous during 
freezing; no sunken DCM. 
Visibly porous; however 
appeared slightly less 
porous than the previous 
samples created with 55 
vol% or 60 vol% 
7% 45 
PBS,  
0.1% 
BSA 
30 minute, stir bar. 
Manual agitation 
every 3-5 minutes. 
Covered. 
Emulsion appeared 
homogenous during 
freezing; no sunken 
DCM during freeze thaw 
cycles. 
Visibly porous; however 
appeared slightly less 
porous than the previous 
samples created with 55 
vol% or 60 vol% 
7% 45 
IGF-1,  
PBS,  
0.1% 
BSA 
30 minute, stir bar. 
Manual agitation 
every 3-5 minutes. 
Covered. 
Emulsion appeared 
homogenous during 
freezing; no sunken 
DCM during freeze thaw 
cycles. 
Visibly porous; however 
appeared slightly less 
porous than the previous 
samples created with 55 
vol% or 60 vol% 
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Figure 5 – Hydrogel batches created with 60 wt% PLGA, 55 vol% DCM in 7% PVA 
with sunken DCM visible after the first freeze thaw cycle, indicating inadequate 
suspension of blank microparticles within the PVA hydrogel and insufficient control of 
the process. 
 
  
 Sunken DCM 
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Figure 6 – SEM wet-mode micrographs of hydrogels created with 60 wt% PLGA and 55 
vol% DCM in 7% PVA. A) Less porous region of the scaffold where microparticles 
(white arrows) densely populate area. 65x magnification. (B-E) Porous regions with 
microparticles (white arrows) dispersed throughout pore structure. 80x magnification. (A-
E) Yellow scale bars are all 200µm. 
A B C 
D E F 
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Figure 7 – Three dimensional rendering of a dry hydrogel created with 60 wt% PLGA 
and 55 vol% DCM in 7% PVA. Scale bar is 200µm.  
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Figure 8  - Swelling ratio, Q, of wet mass over dry mass of hydrogels created with 60 
wt% PLGA, 55 vol% DCM in 7% PVA over time in PBS at 37°C. 
 
 
 
Figure 9 – Swelling ratio, Q, of wet mass over dry mass of Spiller et al.’s previous 
hydrogel design created out of 60 wt% PLGA, 35 vol% DCM in 10% PVA for 8 weeks 
in PBS at 37°C (data highlighted with red box and circles)  [64]. 
01
23
45
67
89
3 days 1 week
Q
 (w
et
 m
as
s/
dr
ym
as
s)
 
Time swelling in PBS 
63 
 
 
 
Figure 10 – Gross view of a dry PVA hydrogel created with 60 wt% PLGA, 45 vol% 
DCM in 7% PVA. 
 
Figure 11 - Wet-mode environmental scanning electron microscopy (ESEM) images of 
PLGA microparticles dispersed throughout PVA hydrogels after 4 days (a and b) in PBS 
at 37ºC. Magnification is 80x. 
200µm 
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Figure 12 - Cumulative IGF-1 release from hydrogels. Error bars represent ± one 
standard deviation, and those that are not visible are smaller than the data point (n=3) 
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Figure 13 - Heterogeneity observed in IGF-1 release from PVA hydrogels. (Blue) PVA 
hydrogels cumulative release of IGF-1 over 73 days, two samples cumulatively released 
more than 3000ng, while one sample cumulatively released approximately 1600ng. 
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Figure 14 - Released IGF-1 induced a cellular response of MCF7 cells and compared 
against known IGF-1 concentrated solutions at the same release concentration. 
Fluorescence was normalized to a negative control of IGF-1 of 0ng/ml (n =3 and 
measured in triplicate, *p < 0.001). Error bars represent ± one standard deviation. 
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CHAPTER 5: INCREASEING CELL SEEDING EFFICIENCY OF PVA 
HYDROGEL AND EVALUATION OF TISSUE ENGINEERING POTENTIAL 
5.1 Introduction 
Previous studies by Spiller et al., have described how the controlled release of 
IGF-1 from non-degradable PVA hydrogels wrapped in PGA fibers has been shown to 
increase cartilage formation and integration with surrounding tissue  [2, 64]. PGA fibers 
were found to be imperative for good cell adhesion because cells do not attach to PVA 
due to being very hydrophilic. The study illustrated how the controlled release of IGF-1 
with a low and high dose (3.33ug and 30ug per hydrogel, respectively) significantly 
enhanced cartilage formation in vivo when the scaffolds were statically seeded with ten 
million immature porcine chondrocytes and implanted subcutaneously in nude mice for 
six weeks. However, there were no significant differences in cartilage formation based on 
dosing despite a 9-fold difference from low to high. The low-dose IGF-1 eluting PVA 
hydrogels cumulatively released 13% of its theoretical loading after 32 days in vitro, 
while the high-dose hydrogels cumulatively released 26% of its theoretical loading after 
46 days in vitro, suggesting further research was necessary on the effect of controlled 
release over time [2]. Additionally, it was suggested that enhanced cell seeding 
techniques and increased porosity of the hydrogel would negate the need for the PGA 
mesh surrounding the PVA hydrogel, and allow direct cartilage proliferation within the 
non-degradable PVA hydrogel.  
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Cellular based therapies are commonly used with biomaterials to improve the 
outcome of a scaffold material in vivo. Seeding cells onto a scaffold prior to implantation 
allow the deposition of ECM to begin during the culturing period and ideally throughout 
the full thickness of a three dimensional scaffold. Static cell seeding is a classic cell 
seeding method where cells will infiltrate the pores of the material and facilitate nutrient 
and waste exchange for cell proliferation  [69].  With larger pores, static cell seeding has 
been shown to be efficient, but it remains a challenge for the cells to migrate through the 
full thickness of a scaffold. One parameter that remains controversial in cell seeding is 
the sample pre-treatment; for example, a hydrogel can be sterilized by soaking in 70% 
ethanol and washed with PBS before cell seeded or cells can be seeded on a sterile, dry 
hydrogel. Some researchers suggest that pre-wetting a sample allows for better nutrient 
exchange, while other say that it is unnecessary  [85]. This treatment has potential to 
significantly affect the efficiency of static cell seeding. Prior to implantation in vivo, the 
most efficient pre-treatment before static cell seeding should be identified. 
Additionally, prior to testing a new material in an orthotopic implantation model, 
a subcutaneous implantation is often performed as a preliminary indication of material 
biocompatibility and efficacy. Oliveira et al. developed gellan gum hydrogels, which 
were seeded with human articular chondrocytes and subsequently implanted 
subcutaneously in the backs of nude mice. Biochemical, histological, immunological and 
molecular analyses were conducted and found that the in vivo study indicated the success 
of the material in regards to effectiveness, biocompatibility, ECM deposition and showed 
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that the material had potential to support cartilage growth as a tissue engineering scaffold  
[86]. Therefore, preliminary in vivo models, such as subcutaneous implantation, provide 
excellent support for further research, optimization and clinical potential.  
Previous studies show that controlled release was sustained for approximately 32 
days, but the PVA hydrogels were not sufficiently porous to support cartilage infiltration. 
Therefore in addition to evaluating the new highly porous hydrogel as an integrative 
cartilage tissue engineering scaffold, this study was also conducted to further understand 
the effects of the controlled release of IGF-1 over time.  
5.2 Methods 
5.2.1 Evaluation of static cell seeding preparation and concentration  
Prior to cell seeding hydrogels, hydrogels were fabricated according to the 
methods described in Section 4.6.1, for implantation in vivo, a small cell adhesion study 
was performed to determine the optimal sample preparation for static cell seeding. Three 
sample preparations were examined: dry, pre-soaked with DMEM for approximately 15 
minutes, or freshly sterilized with 70% ethanol (EtOH) and subsequently washed three 
times with PBS. Of each sample preparation, five hydrogel were seeded with 50,000 
chondrocytes, isolated from five day old pigs approximately two hours after slaughter, 
and cultured for one day to gain an initial assessment of cell attachment for each sample 
preparation group. Hydrogels were minced, dehydrated by lyophilization, and digested in 
papain solution overnight at 65°C.  The papain solution was 125µg/ml papain 10mM HCl, 
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10mM L-cysteine, 0.1M sodium acetate, and 0.05M ethylenediaminetetraacetic acid 
(Sigma-Aldrich). The Picogreen assay (Invitrogen, Grand Island, NY) was used in order 
to assess the amount of cells retained during static cell seeding. The assay uses an 
ultrasensitive fluorescent nucleic acid stain, which is used to quantitatively measure the 
nucleic acid concentration that is then converted into the number of cells. This data was 
used to obtain the number of cells retained and subsequently the fractional cell content 
within the sample. Additionally, a literature validation was performed to determine the 
appropriate cell concentration for static seeding. A minimum of three cartilage-related 
articles were evaluated on scaffold area and volume, cell source, and number of cells 
seeded. Based on the hydrogel design size the optimal cell concentration for static 
seeding was calculated. 
5.2.2 Chondrocyte seeding and in vivo studies 
Hydrogels were sterilized by soaking in 70% ethanol and then washed three times 
with PBS. An institutional review committee of Shanghai Jiao Tong University School of 
Medicine approved all animal study protocols. Mature chondrocytes were isolated from 
cartilage explants taken from the ears of a three month old New Zealand albino rabbits 
through collagenase digestion and subsequent cell straining. Approximately seven million 
chondrocytes in 140µl of cell culture medium (Dulbecco’s Modified Eagle Medium, 
DMEM, containing 10% fetal bovine serum, 4.5g/L glucose, 10mM sodium pyruvate, 
25mM HEPES buffer, and 1% antibiotic/antimycotic solution, Invitrogen, Carlsbad, CA) 
were added to each sample by seeding onto each hydrogel and allowed cells to attach for 
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approximately one hour prior to adding media. The cell-seeded constructs were cultured 
in 20ml medium for 6 days in an incubator maintained at 37°C and 5% CO2 and then 
implanted subcutaneously into the backs of nude mice. A sample from each of the four 
groups (no dose cell seeded and non-cell seeded, and dose cell seeded and non-cell 
seeded) was implanted into each mouse to eliminate inter-animal differences (n=10 per 
group). 
5.2.3 Histological characterization of tissue-hydrogel constructs 
The cartilage-hydrogel constructs were removed after 2 weeks and 5 weeks in 
vivo. The samples were analyzed by gross observation, measured and weighed. Three 
samples from each group were fixed in 4% paraformaledehyde for 3 days at 4°C, 
embedded in paraffin, and sectioned to 5µm. Sections were stained with hematoxylin and 
eosin for overall structure and with Safranin’O and hematoxylin to visualize sulfated 
proteoglycans. Sections were also stained immunohistochemically for the presence of 
type II collagen. Sections were incubated in mouse-anti-human type II collagen primary 
antibody, followed by goat-anti-mouse secondary antibody, and the color was developed 
using 3,3-diaminobenzidine (DAB).  
5.2.4 Biochemical assays 
Cartilage-hydrogel constructs (n=6) were minced, dehydrated by lyophilization, 
and digested in papain solution overnight at 65°C.  The papain solution was 125µg/ml 
papain 10mM HCl, 10mM L-cysteine, 0.1M sodium acetate, and 0.05M 
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ethylenediaminetetraacetic acid (Sigma-Aldrich). The total content of 
glycosaminoglycans (GAGs) was determined by reaction by dimethylmethylene blue dye, 
using shark chondroitin sulfate (Sigma-Aldrich) to generate a standard curve  [87]. The 
total content of collagen was calculated using an orthohydroxyproline assay, which 
measures approximately 10% of the total collagen  [88]. The wet weights of the tissue 
portion of the constructs were calculated by subtracting the mass of the non-cell-seeded 
control from those of the cartilage-hydrogel constructs. The DNA content in the 
constructs was determined using the Picogreen assay (Invitrogen) and converted to 
number of chondrocytes using the conversion factor of 7.7pg of DNA per chondrocyte  
[89]. GAG and collagen contents were compared to those of healthy cartilage obtained 
from the ear of the rabbits.  
In addition, quantitative reverse transcriptase polymerase chain reaction (RT-
PCR) was performed to determine the changes in cartilage-specific gene expression 
(aggrecan and collagen II) in the harvested constructs. Immediately following each 
harvest, to ensure sterility, three cartilage-hydrogel constructs were cut in half; the three 
separate halves were placed in trizol and frozen in -80C for archiving. When prepared to 
extract the RNA, samples were placed in a 4C refrigerator; during the thawing process 
the trizol digested the majority of the sample. Prior to the extraction process, each sample 
was minced using a homogenizer (Model: Pro 200, ProScientific, Inc., Oxford, CT). 
RNA was extracted using a traditional phenol-chloroform method. cDNA was 
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synthesized using a commercially available kit, and RT-PCR was conducted using 
primers of aggrecan and collagen II, with 540 base pairs and 293 base pairs, respectively.   
5.2.5 Statistical analysis 
All data points are represented as the mean ± one standard deviation. Statistical 
significance was determined by one-way analysis of variance (ANOVA) with post-hoc 
analysis by Tukey’s test. P-values less than 0.001 were considered statistically significant. 
5.3 RESULTS & ANALYSIS 
5.3.1 Static cell seeding on dry hydrogel yielded highest efficiency 
Static cell seeding is one of the classic and conventional cell seeding methods 
commonly used in biomaterial and tissue engineering research. However, pre-treatment 
of materials prior to seeding with cells is not often discussed, despite its potential to 
enhance efficiency depending on the material. With PVA being a highly hydrophilic 
material, cells do not bind to the surface of the polymer for ECM deposition. Therefore 
seeding cells directly onto a PVA hydrogel that does not contain a more hydrophobic 
element or controlled release system, would likely result in poor attachment and support 
for tissue engineering [10]. However with increased porosity of the newly designed PVA 
hydrogel in addition to the controlled release of IGF-1 from PLGA microparticles 
suggested the hydrogel had potential to promote cell mobility and attachment. To ensure 
the cell seeding would be as efficient as possible prior to a subcutaneous implantation, 
the hydrogels, with three different pre-treatments, were seeded with 50,000 chondrocytes. 
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The pre-treatments were 1) by sterilizing the hydrogel in 70% ethanol and washing with 
PBS over the course of approximately one hour, 2) pre-wetting a sterile, dry hydrogel 
with DMEM for approximately 10 minutes, and 3) no treatment; a sterile, dry hydrogel.  
The no treatment, sterile, dry hydrogel resulted in the highest percentage of cells 
remaining on the hydrogel matrix after approximately one day of culturing. The dry 
hydrogel retained an average of over 80% of cells seeded onto the scaffold, while 
samples pre-treated with ethanol or DMEM retained less than 25% (Figure 15).  While 
the preliminary study cultured cells for only three hours, the study indicated that the 
classic, pre-wetting, or samples being sterilized via ethanol and a series of washes with 
PBS were not efficient models for cell seeding. The dry hydrogels acted like a sponge 
and soaked in the cell suspension enough to retain over 80% of the cells seeded. 
Additionally, the dry hydrogel’s ability to maintain high efficiency of cell seeding after 
only three hours was indicative of pore size and porosity. Without the large pores with 
high swelling capabilities, cells would not appropriately migrate through the hydrogel as 
was observed after the three hours. Pores were large enough that the cells had the 
potential to reach full thickness into the hydrogel, however histology was not performed 
to determine the depth of cell infiltration after the preliminary study.  In conclusion, 
seeding chondrocytes onto dry, porous, IGF-1 eluting PVA hydrogels provided the 
optimal static cell seeding model for in vitro analysis or to accelerate and enhance 
cellular proliferation and integration with surrounding tissue in vivo. 
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In addition to determining the optimal cell seeding model, the optimal 
concentration of cells to be seeded onto a scaffold based on volume was determined 
through a literature analysis of other hydrogels of similar composition seeding 
chondrocytes (immature/mature), and mesenchymal stem cells. The results found from 
varying hydrogel composition, that the new PVA hydrogel design with a volume of 
approximately 150mm3 required between 7 x 106 – 9.5 x 106 cells per hydrogel for 
optimal cell seeding [90-95]. Comparing this volume of cells to what is required for 
autologous chondrocyte implantation (ACI) (12 x 106 cells), there is a significant 
decrease in cells needed with the new hydrogel design, indicating good clinical potential  
[96]. In conclusion, statically seeding chondrocytes onto dry hydrogels has been shown to 
retain the highest number of seeded cells after three hours of culturing in vivo, suggesting 
similar behavior in vivo. Additionally, a literature analysis confirmed that 7 – 9.5 x 106 
chondrocytes would enhance in vitro/in vivo cartilage tissue engineering for the new PVA 
hydrogel design.  
5.3.2 Effects of controlled release of IGF-1 on cartilage tissue formation and 
integration with hydrogels 
Four experimental groups were implanted subcutaneously in nude mice and 
subsequently harvested at two and five weeks. The sample groups were labeled as: Cells 
with IGF-1, Cells without IGF-1, No-Cell Control without IGF-1, and No-Cell Control 
with IGF-1. The two cell seeded sample groups, with and without IGF-1, were cultured 
for six days in vitro prior to subcutaneous implantation into nude mice to be harvested at 
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two and five weeks. Gross differences in tissue formation between the groups were 
apparent upon harvest of the samples at each time point. Cells with IGF-1 and Cells 
without IGF-1 samples (Figure 16, top row), showed more tissue formation than samples 
with No-cells, with the exception of the five week, Cells without IGF-1 sample (Figure 
16, bottom row), which showed some tissue formation. At each time point, samples with 
tissue formation appeared slightly vascularized, with the five week Cells with IGF-1 
sample (Figure 16, bottom row) showing the most gross vascularization. Vascularization 
may have occurred in the samples due to how thin the samples were and the early burst 
release of IGF-1, which has been shown to promote local angiogenesis [97]. 
Histological analysis of the hydrogel-cartilage constructs at two weeks and five 
weeks using Safranin’O qualitatively shows the presence of sulfated proteoglycans, 
which is indicative of cartilage tissue formation. Pronounced expression is shown on one 
side of the hydrogel sample groups Cells with IGF-1 and Cells without IGF-1 after five 
weeks in vivo (Figure 17D-17F and Figure 17J-17L, respectively). There were also areas 
of concentrated nuclei throughout all samples at both time points (stained black). No 
cartilage formation was observed in the hydrogels without cells. These results indicate 
that the seeded chondrocytes may have the potential to generate new cartilage with or 
without the assistance of IGF-1. 
Immunohistological analysis stained strongly for the presence of collagen II in 
cell-seeded samples with and without IGF-1 after five weeks (Figure 18D-18F and Figure 
77 
 
18J-18L, respectively). Additionally, at two weeks, the same sample groups had a very 
small presence of collagen II within the hydrogel (Figure 18B and 18H). The Cells 
without IGF-1 sample appeared to stain darker than the Cells with IGF-1 sample, 
indicating a higher concentration of collagen II in that region. The higher concentration 
of collagen II observed in the hydrogel without IGF-1 suggests that cell seeding may 
enhance cartilage formation as much as a sample with the controlled release of IGF-1. In 
both the positively stained proteoglycan and collagen II on the Cells with and without 
IGF-1 samples, the tissue was mostly mature and appeared to form on the surface and 
within the superficial hydrogel pores (Figure 17E, 17K and Figure 18E, 18K). 
The large average pore size allowed seeded cells to infiltrate the hydrogel as seen 
in histological and immunohistological analysis. At two weeks, constructs with IGF-1 
had little or no expression of type II collagen and proteoglycans, while at five weeks, 
Cells with and without IGF-1 samples yielded positive expression. Conversely, No-cell 
control, with and without IGF-1 samples did not express collagen II or proteoglycans at 
either time point. In both gross and histological views, vascularization was seen and 
likely a result of concentration gradients of IGF-1 from the hydrogels within the first 
week, since vascularization is not known to occur in chondrocyte-seeded scaffolds 
without the release of growth factors  [28, 98].  
5.3.3 Increases in markers of cartilage over time 
Samples were analyzed for glycosaminoglycan (GAG) and collagen content utilizing biochemical assays derived 
from dimethylmethylene blue dye and hydroxyproline, respectively. The GAG and collagen expressions were 
normalized to the wet weight of the tissue in order to compare to healthy cartilage and also per cell, which is 
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indicative of cell stimulation. After the harvest of the hydrogel-cartilage constructs, GAG expression was not 
significantly different two weeks to five weeks 
(
 
Figure 19a – 19c). During the two week time point, Cells with IGF-1 sample 
GAG expression significantly greater than the No-Cell without IGF-1 samples in the total 
GAGs (mg) (0.929 ± 0.907 and 0.043 ± 0.014, respectively), GAGs per wet weight 
(%ww) (1.027 ± 0.978 and 0.060 ± 0.038, respectively), and GAGs per cell (ng/cell) 
categories (0.640 ± 0.417 and 0.223 ± 0.225, respectively).  Over the five week time 
point, samples exhibited similar trends as the two week samples, with both sample groups 
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seeded with cells expressing higher GAG expression than the control samples without 
cells, but not statistically significant. Furthermore, no significant differences in GAG 
expression were observed during the five week time point or from the two week to five 
week time points.  
Collagen expression significantly increased from two weeks to five weeks in total collagen (mg) (7.64 ± 6.21 and 
23.72 ± 15.30, respectively) and collagen per wet weight of tissue (%ww) (0.088 ± 0.065 and 0.22 ± 0.12, 
respectively) categories 
(
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Figure 19d – 19e). At both time points, Cells with and without IGF-1 samples 
expressed collagen significantly greater than the No-Cell control without IGF-1 sample 
group in total collagen, collagen/cell (ng/cell) and collagen/wet weight (%ww) of tissue 
categories. Additionally, samples seeded with cells were seeded with seven million cells, 
where the sample with IGF-1 at five weeks retained the highest percentage of cells at 
approximately 40%. The No-Cell Control with IGF-1 sample group expressed the lowest 
collagen content out of all sample groups in each category for each time point.  
Two gene markers for cartilage were identified using quantitative reverse 
transcription real-time polymerase chain reaction (RT-PCR). Type II collagen and 
aggrecan expression was significantly enhanced from the Cells with IGF-1 samples 
compared to Cells without IGF-1 samples (Figure 20). There was also a significant 
increase in collagen II expression in the Cells with IGF-1 sample group from the two 
week to the five week time point (dRn) (36.92 ± 48.56 and 220.21 ± 107.61, respectively). 
Additionally, during the two week time point, aggrecan expression in the No-Cell with 
IGF-1 sample group had the highest expression out of all groups (dRn) (94.00 ± 151.07). 
Overall, Cells with IGF-1 samples had the highest expression for both markers after five 
weeks and was significantly higher than Cells without IGF-1 in collagen II expression 
(dRn) (179.56 ± 97.37 and 19.02 ± 15.78, respectively). 
Samples seeded with chondrocytes with and without IGF-1 expressed more 
glycosaminoglycans (GAGs) and collagen II content than the sample group without IGF-
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1 and cells at both time points. Significant increases in collagen were observed from the 
IGF-1 cell seeded samples at five weeks in total collagen content and collagen /wet 
weight (%ww) compared to samples at two weeks. However, at two weeks GAG 
expression was significantly higher in the Cell with IGF-1 samples than No-Cell without 
IGF-1 samples. Additionally, GAG expression in the Cells with IGF-1 decreased two to 
five weeks, suggesting that protein deposition over time changed during the healing 
process. Subcutaneous wound healing in mice has shown an overexpression of GAG 
during the early phases of wound healing, which may suggest why samples harvested at 
two weeks had a higher expression than at five weeks when GAG expression returns to a 
normal level during remodeling  [99]. Interestingly, the expression of GAGs/wet weight 
(%ww) was considerably less than the auricular cartilage control, while the expression of 
collagen II/wet weight (%ww) was considerably more than the auricular cartilage control. 
In conclusion, the biochemical and gene marker analysis show that the Cells with IGF-1 
samples significantly increased cartilage-specific markers over time compared to No-
Cells without IGF-1 samples; however, the Cells with IGF-1 not significantly different 
than Cells without IGF-1 samples indicating that cell seeding was imperative to the 
increase in cell attachment within the hydrogel pores. 
5.4 Conclusions 
The increased pore size and porosity allowed chondrocytes to be seeded directly 
onto the surface of the PVA hydrogel, which was an improvement over the previous 
design what used a PGA mesh to surround the PVA hydrogel [2]. Chondrocytes seeded 
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directly onto the hydrogels with and without IGF-1, were found to infiltrate the 
superficial pores as confirmed in histological and immunohistological analysis. Full 
thickness infiltration of cells and ECM deposition was not observed likely due to the pre-
wet cell seeding model. The original experimental plan intended samples to be seeded dry, 
because statically cell seeding onto dry PVA hydrogel was found to retain the highest 
number of cells in vitro; however, hydrogels were sterilized with 70% ethanol due to the 
dry, sterile sample container being damaged during shipment. As a result of the reduced 
efficiency of chondrocytes infiltrating the hydrogel, non-cartilage-like expression and 
vascularization were observed. 
The biochemical and gene marker analysis showed that chondrocyte-seeded 
hydrogels without the controlled release of IGF-1 resulted in cartilage-specific expression 
as high as chondrocyte-seeded hydrogels with the controlled release of IGF-1. IGF-1 
efficacy in vivo may have been diminished due to samples losing bioactivity during 
transit to China or that auricular chondrocytes did not behave the same as articular 
chondrocytes. The success of cartilage formation on samples seeded with chondrocytes 
without IGF-1 suggests that while the controlled release of IGF-1 has been shown to 
significantly increase expression, cell seeding is also very important for cartilage tissue 
engineering in vivo.  
  
83 
 
 
Figure 15 – Fractional cell content, as calculated by dividing the number of cells 
obtained from the Picogreen assay by the number of cells seeded onto the hydrogels, for 
each sample preparation of pre-soaking in DMEM, pre-sterilization with EtOH and 
washing with PBS or dry.  
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Figure 16 - Gross views of cartilage-hydrogel constructs after subcutaneous implantation 
for two weeks (top row) and five weeks (bottom row). 
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Figure 17 - Histological analyses of cross-sections of harvested constructs, using 
Safranin’O (proteoglycans, red) and hematoxylin (cell nuclei, blue). IGF-1 cell seeded 
and no IGF-1 cell seeded samples at five weeks exhibited positive staining on one side of 
the hydrogels (D-F and J-L, respectively). J) Sample deformed during processing. Scale 
bars are 5mm, 500µm, and 200µm respective of the 12.5x, 100x and 200x zoom.  
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Figure 18 - Immunohistological analyses of cross-sections of harvested constructs for 
collagen II expression (brown). IGF-1 cell seeded and no IGF-1 cell seeded samples at 
five weeks exhibited strong staining on one side of the hydrogels (D-F and J-L, 
respectively). J) Sample deformed during processing. Scale bars are 5mm, 500µm, and 
200µm respective of the 12.5x, 100x and 200x zoom. 
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Figure 19 – (a-c) Biochemical analysis for glycosaminoglycans (GAGs) and (d-f) 
collagen of cartilage-hydrogel constructs (2 week, n=7; 5 week, n=6). Error bars 
represent ± one standard deviation. (*) Represents statistical significance between sample 
groups, whereas (**) represents statistical significance between time points within one 
sample group (*, **p < 0.001).  
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Figure 20 - Real-time quantitative polymerase chain reaction (Q-PCR), a) aggrecan and 
b) collagen II; n=3. Error bars represent ± one standard deviation. (*) Represents 
statistical significance between sample groups, whereas (**) represents statistical 
significance between time points within one sample group (*, **p < 0.001). 
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CHAPTER 6: CONCLUSIONS & FUTURE WORK 
6.1 Conclusions 
This research aimed to improve a previously designed hydrogel designed by 
Spiller et al. Spiller et al.’s previous design demonstrated that the controlled release of 
IGF-1 from a PGA fiber wrapped PVA hydrogel resulted in increased cartilage formation 
and integration with surrounding tissue in vivo; however, the pore size was too small 
(average pore size ranged from 60 to 100µm, with porosity ranging from 60-70%) to 
allow cartilage tissue to grow throughout the full thickness of the implant. Therefore the 
main purpose and aims of this study were to increase the porosity of PVA hydrogels 
while maintaining the controlled release system of IGF-1. Additionally, the work sought 
to maintain processing parameters of the PVA hydrogel with microparticles loaded with 
IGF-1 created from PLGA in order to directly compare the new hydrogel design to the 
previous design. Various methods were attempted in order to accomplish this, but by 
increasing the volume of organic solvent in the oil phase and decreasing the 
concentration of PVA resulted in highly porous PVA hydrogels. The hydrogels resulted 
in an average pore size and porosity of approximately 40-600µm and 84%, respectively. 
This was an improvement over the previously designed hydrogel. The new design greatly 
improved hydrogel swelling in addition to maintaining the controlled release of IGF-1. 
The new hydrogel design sustained release of IGF-1 released for 73 days and remained 
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biologically active for the first 11 days in vitro. The hydrogel’s good performance in vitro 
suggested good potential in vivo.  
Prior to implanting in vivo, the optimal cell seeding concentration and method 
were identified. Through literature analysis approximately 7 x 106 million cells seeded 
onto the hydrogel volume (~150mm3) was found to provide enough cells in vivo for good 
cell infiltration and growth. Additionally with a short-term cell seeing experiment, direct, 
static, seeding onto the highly porous PVA hydrogel was found to retain over 80% of 
seeded cells in vitro. The new design provided significant improvement over the previous 
design by allowing direct cell seeding onto the PVA hydrogel rather than onto PGA 
fibers wrapped around a PVA hydrogel. 
The new hydrogel was evaluated in vivo, via a subcutaneous implantation model 
in nude mice. The study found increases in cartilage-specific expression in samples 
seeded with chondrocytes with and without IGF-1 over time, as confirmed with 
histological, biochemical and gene expression analysis. While there was some error in the 
biochemical and genetic analysis, the results were consistent with the heterogeneous, but 
bioactive release of IGF-1 from the PVA hydrogels. The increased expression of 
cartilage-specific markers indicated that both the IGF-1 and cell seeding together were 
important for cartilage growth within the hydrogel pores, but also that seeding cells onto 
a highly porous PVA hydrogel, alone, may have similar benefits in tissue engineering as 
a controlled release system. Additionally, while samples were harvested at two and five 
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weeks in vivo, the in vitro analysis of the sustained release of IGF-1 for 73 days, suggests 
that additional tissue formation and infiltration within hydrogel pores may have potential 
to do so beyond five weeks in vivo 
 Overall, the results of this work show that directly seeding chondrocytes onto the 
highly porous, IGF-1 eluting, PVA hydrogel can improve cartilage formation within the 
pores of the non-degradable material for enhanced implant integration with surrounding 
tissue.  
6.2 Future Work 
This research provided a platform for cell attachment to a non-degradable PVA 
hydrogels known for their excellent biocompatible, mechanical and swelling properties 
that closely mimic native cartilage tissue. However, with increased porosity, mechanical 
stability and pore interconnectivity is often compromised. It has been suggested that with 
improved cell seeding techniques, seeded cells are able to disperse throughout the full 
thickness of the material, depositing new ECM and increasing formation of cartilage 
tissue throughout the pores of the material. The new cartilage tissue has the potential to 
compensate for the initial decrease in mechanical strength of the highly porous material. 
Therefore, future work would characterize the minimum mechanical strength and 
stiffness required of a scaffold and subsequently the necessary amount of tissue formation 
to mimic native cartilage. Additionally, a consistent and accurate method to measure pore 
interconnectivity would further evaluate the increased pore structure. Employing dynamic 
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cell seeding methods such as perfusion, centrifugation, vacuum, or electrostatic seeding 
may improve cell migration through the full thickness of the hydrogel. A more clinically 
viable cell source could also be investigated, such a mechenchymal stem cells isolated 
from bone marrow. 
Another important aspect to the future work of cartilage tissue engineering would 
be to test materials in a more physiologically relevant in vivo model. Subcutaneous 
studies mainly validate the material’s biocompatibility rather than it’s ability to support 
cartilage tissue engineering. As previously discussed, mechanical forces and dynamic 
loading on chondrocytes and the signaling pathways significantly affects the 
differentiation and maintenance of appropriate phenotype in cartilage tissue. Therefore 
testing new materials under mechanical force and dynamic loading will be imperative for 
future research. 
Other viable future work includes a hydrogel re-design to further improve 
integration with the surrounding tissue along and negate the need for cell seeding. 
Another way to potential improve integration of implant in vivo, would be to create a 
IGF-1 eluting PVA hydrogel that could also introduce a temporally and spatially 
controlled dose of an enzyme to lightly digest the surrounding tissue. Once the 
surrounding tissue’s chondrocytes are freed from the surface of the defect, the controlled 
release of IGF-1 would create concentration gradients and recruit the cells into the 
scaffold. This research would require significant background investigation on the 
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interaction between the growth factor and enzyme to ensure the two do not interfere with 
one another; however would address implant integration, cell source, and provide a 
superior long-term solution for cartilage repair. 
  
94 
 
LIST OF REFERENCES 
[1] N. Mahmoudifar and P. M. Doran, "Chondrogenesis and cartilage tissue engineering: 
the longer road to technology development,"  Trends Biotechnol., vol. 30, pp. 166-176, 3, 
2012.  
[2] K. L. Spiller, Y. Liu, J. L. Holloway, S. A. Maher, Y. Cao, W. Liu, G. Zhou and A. 
M. Lowman, "A novel method for the direct fabrication of growth factor-loaded 
microspheres within porous nondegradable hydrogels: Controlled release for cartilage 
tissue engineering,"  J.  Controlled Release, vol. 157, pp. 39-45, 2012.  
[3] S. A. Maher, R. L. Mauck, L. Rackwitz and R. S. Tuan, "A nanofibrous cell-seeded 
hydrogel promotes integration in a cartilage gap model,"  Journal of Tissue Engineering 
and Regenerative Medicine, vol. 4, pp. 25-29, 2010.  
[4] R. L. Mauck and J. A. Burdick, "Engineering Cartilage Tissue,"  pp. 493-520, 2011.  
[5] B. Obradovic, I. Martin, R. Padera, S. Treppo, L. Freed and G. Vunjak-Novakovic, 
"Integration of engineered cartilage,"  J.  Orthop.  Res., vol. 19, pp. 1089-1097, 2001.  
[6] J. Temenoff and A. Mikos, "Review: tissue engineering for regeneration of articular 
cartilage,"  Biomaterials, vol. 21, pp. 431-440, 2000.  
[7] A. Hoffman, "Hydrogels for biomedical applications,"  Bioartificial Organs Iii: 
Tissue Sourcing, Immunoisolation, and Clinical Trials, vol. 944, pp. 62-73, 2001.  
[8] J. J. Jagur-Grodzinski, "Polymers for tissue engineering, medical devices, and 
regenerative medicine. Concise general review of recent 
studies,"  Polym.  Adv.  Technol., vol. 17, pp. 395-418, 2006.  
[9] M. B. Murphy and A. G. Mikos, "Chapter twenty-two - polymer scaffold fabrication," 
in Principles of Tissue Engineering (Third Edition), Robert Lanza A2Robert Langer and 
Joseph VacantiA2 Robert Lanza,Robert Langer and Joseph Vacanti, Eds. Burlington: 
Academic Press, 2007, pp. 309-321. 
[10] K. L. Spiller, J. L. Holloway, M. E. Gribb and A. M. Lowman, "Design of semi-
degradable hydrogels based on poly(vinyl alcohol) and poly(lactic-co-glycolic acid) for 
cartilage tissue engineering,"  Journal of Tissue Engineering and Regenerative Medicine, 
vol. 5, pp. 636-647, 2011.  
95 
 
[11] S. A. Maher, S. B. Doty, P. A. Torzilli, S. Thornton, A. M. Lowman, J. D. Thomas, 
R. Warren, T. M. Wright and E. Myers, "Nondegradable hydrogels for the treatment of 
focal cartilage defects,"  Journal of Biomedical Materials Research Part A, vol. 83A, pp. 
145-155, 2007.  
[12] P. M. Scholten, K. W. Ng, K. Joh, L. P. Serino, R. F. Warren, P. A. Torzilli and S. 
A. Maher, "A semi-degradable composite scaffold for articular cartilage 
defects,"  Journal of Biomedical Materials Research Part A, vol. 97A, pp. 8-15, 2011.  
[13] J. J. Xie, "Mechano-Active Scaffold Design Based on Microporous Poly(L-lactide-
co- -caprolactone) for Articular Cartilage Tissue Engineering: Dependence of Porosity on 
Compression Force-Applied Mechanical Behaviors,"  Tissue Eng., vol. 12, pp. 449-458, 
2006.  
[14] N. Peppas, J. Hilt, A. Khademhosseini and R. Langer, "Hydrogels in biology and 
medicine: From molecular principles to bionanotechnology RID A-9435-2010,"  Adv 
Mater, vol. 18, pp. 1345-1360, 2006.  
[15] S. Lien, L. Ko and T. Huang, "Effect of pore size on ECM secretion and cell growth 
in gelatin scaffold for articular cartilage tissue engineering,"  Acta Biomaterialia, vol. 5, 
pp. 670-679, 2, 2009.  
[16] N. Palastanga and R. W. Soames, Anatomy and Human Movement: Structure and 
Function. Elsevier Health Systems, 2011. 
[17] M. Huber, "Anatomy, Biochemistry, and Physiology of Articular 
Cartilage,"  Invest.  Radiol., vol. 35, pp. 573-580, 2000.  
[18] A. M. Bhosale and J. B. - Richardson, "Articular cartilage: structure, injuries and 
review of management,"  British Medical Bulletin, pp. 77, 2008. 
[19] K. A. Athanasiou, E. M. Darling and J. C. Hu, Articular Cartilage Tissue 
Engineering: A Series of Lectures on Tissue Engineering. Morgan & Claypool 
Publishers, 2009. 
[20] P. B. Saadeh, "Human Cartilage Engineering Chondrocyte Extraction, Proliferation, 
and Characterization for Construct Development,"  Ann.  Plast.  Surg., vol. 42, pp. 509-
513, 1999.  
[21] A. Newman, "Articular cartilage repair,"  Am.  J.  Sports Med., vol. 26, pp. 309-324, 
1998.  
96 
 
[22] M. DelCarlo, "Chondrocyte cell death mediated by reactive oxygen species-
dependent activation of PKC-betaI,"  American Journal of Physiology: Cell Physiology, 
vol. 290, pp. C802-C811, 2005.  
[23] L. J. Bonassar, "Mechanical and Physicochemical Regulation of the Action of 
Insulin-Like Growth Factor-I on Articular Cartilage,"  Arch.  Biochem.  Biophys., vol. 
379, pp. 57-63, 2000.  
[24] L. C. Davies, "The Potential of IGF-1 and TGFβ1 for Promoting “Adult” Articular 
Cartilage Repair: An Study,"  Tissue Engineering.Part A, vol. 14, pp. 1251-1261, 2008.  
[25] J. Wang, "Insulin-like growth factor 1-induced interleukin-1 receptor II overrides the 
activity of interleukin-1 and controls the homeostasis of the extracellular matrix of 
cartilage,"  Arthritis Rheum., vol. 48, pp. 1281-1291, 2003.  
[26] A. Moustakas, K. Pardali, A. Gaal and C. Heldin, "Mechanisms of TGF-β signaling 
in regulation of cell growth and differentiation,"  Immunol.  Lett., vol. 82, pp. 85-91, 
2002.  
[27] E. Blaney Davidson, "Reduced transforming growth factor-beta signaling in 
cartilage of old mice: role in impaired repair capacity,"  Arthritis Research & Therapy, 
vol. 7, pp. R1338-R1347, 2005.  
[28] C. Kaps, C. Bramlage, H. Smolian, A. Haisch, U. Ungethüm, G. Burmester, M. 
Sittinger, G. Gross and T. Häupl, "Bone morphogenetic proteins promote cartilage 
differentiation and protect engineered artificial cartilage from fibroblast invasion and 
destruction,"  Arthritis & Rheumatism, vol. 46, pp. 149-162, 2002.  
[29] M. Mattioli-Belmonte, A. Gigante, R. Muzzarelli, R. Politano, A. De Benedittis, N. 
Specchia, A. Buffa, G. Biagini and F. Greco, "N,N-dicarboxymethyl chitosan as delivery 
agent for bone morphogenetic protein in the repair of articular cartilage,"  Medical and 
Biological Engineering and Computing, vol. 37, pp. 130-134, 1999.  
[30] S. Degala, W. R. Zipfel and L. J. Bonassar, "Chondrocyte calcium signaling in 
response to fluid flow is regulated by matrix adhesion in 3-D alginate 
scaffolds,"  Arch.  Biochem.  Biophys., vol. 505, pp. 112-117, 2011.  
[31] L. M. Kock, R. M. Schulz, C. C. van Donkelaar, C. B. Thümmler, A. Bader and K. 
Ito, "RGD-dependent integrins are mechanotransducers in dynamically compressed 
tissue-engineered cartilage constructs,"  J.  Biomech., vol. 42, pp. 2177-2182, 2009.  
97 
 
[32] S. J. Bryant and K. S. Anseth, "Hydrogel properties influence ECM production by 
chondrocytes photoencapsulated in poly(ethylene glycol) 
hydrogels,"  J.  Biomed.  Mater.  Res., vol. 59, pp. 63-72, 2002.  
[33] X. Vial and F. M. Andreopoulos, "Novel Biomaterials for Cartilage Tissue 
Engineering,"  Current Rheumatology Reviews, vol. 5, pp. 51, 2009.  
[34] C. G. Helmick, D. T. Felson, R. C. Lawrence, S. Gabriel, R. Hirsch, C. K. Kwoh, M. 
H. Liang, H. M. Kremers, M. D. Mayes, P. A. Merkel, S. R. Pillemer, J. D. Reveille, J. H. 
Stone and National Arthritis Data Workgroup, "Estimates of the prevalence of arthritis 
and other rheumatic conditions in the United States: Part I,"  Arthritis & Rheumatism, 
vol. 58, pp. 15-25, 2008.  
[35] R. Bitton, "The Economic Burdan of Osteoarthritis,"  The American Journal of 
Managed Care, vol. 15, pp. S230, 2009.  
[36] J. B. Moseley, A. F. Anderson, J. E. Browne, B. R. Mandelbaum, L. J. Micheli, F. 
Fu and C. Erggelet, "Long-Term Durability of Autologous Chondrocyte 
Implantation,"  The American Journal of Sports Medicine, pp. 238, . 
[37] K. Zaslav, B. Cole, R. Brewster, T. DeBerardino, J. Farr, P. Fowler and C. Nissen, 
"A Prospective Study of Autologous Chondrocyte Implantation in Patients With Failed 
Prior Treatment for Articular Cartilage Defect of the Knee: Results of the Study of the 
Treatment of Articular Repair (STAR) Clinical Trial,"  Am.  J.  Sports Med., 2008.  
[38] J. D. Kretlow and A. G. Mikos, "From material to tissue: Biomaterial development, 
scaffold fabrication, and tissue engineering,"  AIChE J., vol. 54, pp. 3048-3067, 2008.  
[39] J. Drury and D. Mooney, "Hydrogels for tissue engineering: scaffold design 
variables and applications,"  Biomaterials, vol. 24, pp. 4337-4351, 2003.  
[40] M. Lutolf and J. Hubbell, "Synthetic biomaterials as instructive extracellular 
microenvironments for morphogenesis in tissue engineering,"  Nat.  Biotechnol., vol. 23, 
pp. 47-55, 2005.  
[41] P. G. Chao, S. Yodmuang, X. Wang, L. Sun, D. L. Kaplan and G. Vunjak-
Novakovic, "Silk hydrogel for cartilage tissue engineering,"  Journal of Biomedical 
Materials Research Part B: Applied Biomaterials, vol. 95B, pp. 84-90, 2010.  
[42] C. Nuttelman, D. Mortisen, S. Henry and K. Anseth, "Attachment of fibronectin to 
poly(vinyl alcohol) hydrogels promotes NIH3T3 cell adhesion, proliferation, and 
migration,"  J.  Biomed.  Mater.  Res., vol. 57, pp. 217-223, 2001.  
98 
 
[43] T. H. Alexander, A. B. Sage, A. C. Chen, B. L. Schumacher, E. Shelton, K. Masuda, 
R. L. Sah and D. Watson, "Insulin-like Growth Factor-I and Growth Differentiation 
Factor-5 Promote the Formation of Tissue-Engineered Human Nasal Septal 
Cartilage,"  Tissue Engineering Part C-Methods, vol. 16, pp. 1213-1221, 2010.  
[44] Carticept Medical, "Cartiva™ SCI,"  vol. 2012, 2010.  
[45] C. Chou, W. T. K. Cheng, C. Lin, C. Chang, C. Tsai and F. Lin, "TGF-?1 
immobilized tri-co-polymer for articular cartilage tissue engineering,"  Journal of 
Biomedical Materials Research Part B: Applied Biomaterials, vol. 77B, pp. 338-348, 
2006.  
[46] P. Julkunen, "Relationships between Structure, Composition and Function of 
Articular Cartilage: Studies based on Fibril Reinforced Poroviscoelastic 
Modeling,"  Kuopio University Library, Finland, 2008.  
[47] K. L. Spiller, S. J. Laurencin, D. Charlton, S. A. Maher and A. M. Lowman, 
"Superporous hydrogels for cartilage repair: Evaluation of the morphological and 
mechanical properties,"  Acta Biomaterialia, vol. 4, pp. 17-25, 1, 2008.  
[48] J. Tessmar, T. Holland and A. Mikos, "Salt leaching for polymer scaffolds," in 
Scaffolding in Tissue EngineeringAnonymous CRC Press, 2005, pp. 111-124. 
[49] M. Sokolsky-Papkov, K. Agashi, A. Olaye, K. Shakesheff and A. J. Domb, 
"Polymer carriers for drug delivery in tissue engineering,"  Adv.  Drug Deliv.  Rev., vol. 
59, pp. 187-206, 2007.  
[50] K. Whang, C. H. Thomas, K. E. Healy and G. Nuber, "A novel method to fabricate 
bioabsorbable scaffolds,"  Polymer, vol. 36, pp. 837-842, 1995.  
[51] J. J. Yoon, J. H. Kim and T. G. Park, "Dexamethasone-releasing biodegradable 
polymer scaffolds fabricated by a gas-foaming/salt-leaching method,"  Biomaterials, vol. 
24, pp. 2323-2329, 2003.  
[52] H. J. Chung and T. G. Park, "Surface engineered and drug releasing pre-fabricated 
scaffolds for tissue engineering,"  Adv.  Drug Deliv.  Rev., vol. 59, pp. 249-262, 2007.  
[53] J. J. Yoon, H. J. Chung, H. J. Lee and T. G. Park, "Heparin-immobilized 
biodegradable scaffolds for local and sustained release of angiogenic growth 
factor,"  Journal of Biomedical Materials Research Part A, vol. 79A, pp. 934-942, 2006.  
99 
 
[54] T. Wang, M. Turhan and S. Gunasekaran, "Selected properties of pH-sensitive, 
biodegradable chitosan?poly(vinyl alcohol) hydrogel,"  Polym.  Int., vol. 53, pp. 911-918, 
2004.  
[55] P. Ghosh and S. Ray, "Influence of Process Parameters on the Porosity Content in 
Al(Mg)--Al2O3 Cast Particulate Composite Produced by Vortex Method,"  Transactions 
of the American Foundrymen's Society, vol. 96, pp. 775-782, 1989.  
[56] M. Borden, M. Attawia, Y. Khan and C. T. Laurencin, "Tissue engineered 
microsphere-based matrices for bone repair:: design and evaluation,"  Biomaterials, vol. 
23, pp. 551-559, 2002.  
[57] K. Haibach, A. Menner, R. Powell and A. Bismarck, "Tailoring mechanical 
properties of highly porous polymer foams: Silica particle reinforced polymer foams via 
emulsion templating,"  Polymer, vol. 47, pp. 4513-4519, 2006.  
[58] S. B. Lee, Y. H. Kim, M. S. Chong, S. H. Hong and Y. M. Lee, "Study of gelatin-
containing artificial skin V: fabrication of gelatin scaffolds using a salt-leaching 
method,"  Biomaterials, vol. 26, pp. 1961-1968, 5, 2005.  
[59] W. Rasband, ImageJ. Bethesda,  National Institutes of Health, 1997.  
[60] Y. Chiu, "Generation of Porous Poly(Ethylene Glycol) Hydrogels by Salt 
Leaching,"  Tissue Engineering.Part C, Methods, vol. 16, pp. 905-912, 2010.  
[61] K. L. Spiller, S. J. Laurencin and A. M. Lowman, "Characterization of the behavior 
of porous hydrogels in model osmotically-conditioned articular cartilage 
systems,"  Journal of Biomedical Materials Research Part B: Applied Biomaterials, vol. 
90B, pp. 752-759, 2009.  
[62] M. Dauben, K. Reichert, P. Huang and J. Fock, "Preparation of polymeric porous 
materials by interparticle crosslinking,"  Polymer, vol. 37, pp. 2827-2830, 1996.  
[63] N. N. Annabi, "Controlling the Porosity and Microarchitecture of Hydrogels for 
Tissue Engineering,"  Tissue Engineering.Part B, Reviews, vol. 16, pp. 371-383, 2010.  
[64] K. L. Spiller, "Semi-degradable, multi-functional hydrogels for the repair of articular 
cartilage defects,"  iDEA E-Repository and Archives, June 10, 2010, 2010.  
[65] C. C. M. Hassan, "Structure and Morphology of Freeze/Thawed PVA 
Hydrogels,"  Macromolecules, vol. 33, pp. 2472-2479, 2000.  
100 
 
[66] Y. Yang, T. Chung and N. Ping Ng, "Morphology, drug distribution, and in vitro 
release profiles of biodegradable polymeric microspheres containing protein fabricated 
by double-emulsion solvent extraction/evaporation method,"  Biomaterials, vol. 22, pp. 
231-241, 2001.  
[67] F. M. Plieva, M. Karlsson, M. Aguilar, D. Gomez, S. Mikhalovsky and I. Y. Galaev', 
"Pore structure in supermacroporous polyacrylamide based cryogels,"  Soft Matter, pp. 
303, . 
[68] O. Ariga, M. Kato, T. Sano, Y. Nakazawa and Y. Sano, "Mechanical and kinetic 
properties of PVA hydrogel immobilizing β-galactosidase,"  J.  Ferment.  Bioeng., vol. 
76, pp. 203-206, 1993.  
[69] C. Ji, A. Khademhosseini and F. Dehghani, "Enhancing cell penetration and 
proliferation in chitosan hydrogels for tissue engineering applications,"  Biomaterials, 
vol. 32, pp. 9719-9729, 2011.  
[70] L. Meinel, O. E. Illi, J. Zapf, M. Malfanti, H. Peter Merkle and B. Gander, 
"Stabilizing insulin-like growth factor-I in poly(d,l-lactide-co-glycolide) 
microspheres,"  J.  Controlled Release, vol. 70, pp. 193-202, 2001.  
[71] W. M. Obeidat, "Recent Patents Review in Microencapsulation of Pharmaceuticals 
Using the Emulsion Solvent Removal Methods,"  Recent Patents on Drug Delivery & 
Formulation, vol. 3, pp. 178-192, 2009.  
[72] B. A. Shirley and M. S. Hora, "IGF-1 composition and its use," US Patent 7335639,  
2008. 
[73] F. Wang, Z. Li, M. Khan, K. Tamama, P. Kuppusamy, W. R. Wagner, C. K. Sen and 
J. Guan, "Injectable, rapid gelling and highly flexible hydrogel composites as growth 
factor and cell carriers,"  Acta Biomaterialia, vol. 6, pp. 1978-1991, 2010.  
[74] K. Y. Lee, T. Nakagawa, T. Okano, R. Hori, K. Ono, Y. Tabata, S. H. Lee and J. Ito, 
"Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea 
using gelatin hydrogel,"  Otol.  Neurotol., vol. 28, pp. 976-981, 2007.  
[75] J. Elisseeff, "Controlled-release of IGF-I and TGF-β1 in a photopolymerizing 
hydrogel for cartilage tissue engineering,"  Journal of Orthopaedic Research, vol. 19, pp. 
1098-1104, 2001.  
[76] R. M. Capito, "Collagen scaffolds for nonviral IGF-1 gene delivery in articular 
cartilage tissue engineering,"  Gene Ther., vol. 14, pp. 721-732, 2007.  
101 
 
[77] M. P. Brugts, "Normal Values of Circulating Insulin-Like Growth Factor-I 
Bioactivity in the Healthy Population: Comparison with Five Widely Used IGF-I 
Immunoassays,"  J.  Clin.  Endocrinol.  Metab., vol. 93, pp. 2539-2545, 2008.  
[78] A. Jaklenec, A. Hinckfuss, B. Bilgen, D. M. Ciombor, R. Aaron and E. Mathiowitz, 
"Sequential release of bioactive IGF-I and TGF-beta(1) from PLGA microsphere-based 
scaffolds RID B-3096-2009,"  Biomaterials, vol. 29, pp. 1518-1525, 2008.  
[79] Y. Yeo and K. Park, "Control of encapsulation efficiency and initial burst in 
polymeric microparticle systems,"  Arch.  Pharm.  Res., vol. 27, pp. 1-12, 2004.  
[80] Y. Yang, T. Chung and N. Ng, "Morphology, drug distribution, and in vitro release 
profiles of biodegradable polymeric microspheres containing protein fabricated by 
double-emulsion solvent extraction/evaporation method,"  Biomaterials, vol. 22, pp. 231-
241, 2001.  
[81] T. Vermonden, R. Censi and W. E. Hennink, "Hydrogels for Protein 
Delivery,"  Chem.   Rev., vol. 112, pp. 2853, 2012. 
[82] M. Grazia Cascone, Z. Zhu, F. Borselli and L. Lazzeri, "Poly(vinyl alcohol) 
hydrogels as hydrophilic matrices for the release of lipophilic drugs loaded in PLGA 
nanoparticles,"  Journal of Materials Science: Materials in Medicine, vol. 13, pp. 29-32, 
2002.  
[83] Y. Li, "The Effects of Insulin-Like Growth Factor-1 and Basic Fibroblast Growth 
Factor on the Proliferation of Chondrocytes Embedded in the Collagen Gel Using an 
Integrated Microfluidic Device,"  Tissue Engineering.Part C, Methods, vol. 16, pp. 1267-
1275, 2010.  
[84] S. Lee and H. Shin, "Matrices and scaffolds for delivery of bioactive molecules in 
bone and cartilage tissue engineering,"  Adv.  Drug Deliv.  Rev., vol. 59, pp. 339-359, 
2007.  
[85] G. Vunjak-Novakovic and M. Radisic, "Cell seeding of polymer scaffolds," in 
Biopolymer Methods in Tissue Engineering, illustrated ed., A. P. Hollander and P. V. 
Hatton, Eds. Humana Press, 2004, pp. 131. 
[86] J. T. Oliveira, "Performance of new gellan gum hydrogels combined with human 
articular chondrocytes for cartilage regeneration when subcutaneously implanted in nude 
mice,"  Journal of Tissue Engineering and Regenerative Medicine, vol. 3, pp. 493-500, 
2009.  
102 
 
[87] R. W. Farndale, D. J. Buttle and A. J. Barrett, "Improved quantitation and 
discrimination of sulphated glycosaminoglycans by use of dimethylmethylene 
blue,"  Biochimica Et Biophysica Acta (BBA) - General Subjects, vol. 883, pp. 173-177, 
1986.  
[88] J. F. Woessner Jr., "The determination of hydroxyproline in tissue and protein 
samples containing small proportions of this imino acid,"  Arch.  Biochem.  Biophys., vol. 
93, pp. 440-447, 1961.  
[89] Y. KIM, R. SAH, J. DOONG and A. GRODZINSKY, "Fluorometric Assay of Dna 
in Cartilage Explants using Hoechst-33258,"  Anal.  Biochem., vol. 174, pp. 168-176, 
1988.  
[90] C. S. D. Lee, J. P. Gleghorn, N. Won Choi, M. Cabodi, A. D. Stroock and L. J. 
Bonassar, "Integration of layered chondrocyte-seeded alginate hydrogel 
scaffolds,"  Biomaterials, vol. 28, pp. 2987-2993, 7, 2007.  
[91] E. Liao, M. Yaszemski, P. Krebsbach and S. Hollister, "Tissue-engineered cartilage 
constructs using composite hyaluronic acid/collagen I hydrogels and designed 
poly(propylene fumarate) scaffolds."  Tissue Eng, pp. 537-50, . 
[92] S. Terada, H. Yoshimoto, J. R. Fuchs, M. Sato, I. Pomerantseva, M. K. Selig, D. 
Hannouche and J. P. Vacanti, "Hydrogel optimization for cultured elastic chondrocytes 
seeded onto a polyglycolic acid scaffold*,"  Journal of Biomedical Materials Research 
Part A, vol. 75A, pp. 907-916, 2005.  
[93] C. Chang, H. Liu, C. Lin, C. Chou and F. Lin, "Gelatin–chondroitin–hyaluronan tri-
copolymer scaffold for cartilage tissue engineering,"  Biomaterials, vol. 24, pp. 4853-
4858, 2003.  
[94] Y. Ohyabu, T. Adegawa, T. Yoshioka, T. Ikoma, T. Uemura and J. Tanaka, 
"Cartilage regeneration using a porous scaffold, a collagen sponge incorporating a 
hydroxyapatite/chondroitinsulfate composite,"  Materials Science and Engineering: B, 
vol. 173, pp. 204-207, 2010.  
[95] T. B. F. Woodfield, J. Malda, J. de Wijn, F. Péters, J. Riesle and C. A. van 
Blitterswijk, "Design of porous scaffolds for cartilage tissue engineering using a three-
dimensional fiber-deposition technique,"  Biomaterials, vol. 25, pp. 4149-4161, 2004.  
[96] T. A. Mayhew, G. R. Williams, M. A. Senica, G. Kuniholm and G. C. Du Moulin, 
"Validation of a quality assurance program for autologous cultured chondrocyte 
implantation,"  Tissue Eng., vol. 4, pp. 325-334, 1998.  
103 
 
[97] E. Conti, M. B. Musumeci, G. Egidy Assenza, G. Quarta, C. Autore and M. Volpe, 
"Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease 
Treatment Option?"  Cardiovascular & Hematological Agents in Medicinal Chemistry, 
vol. 6, pp. 258, 2008.  
[98] R. Westreich, M. Kaufman, P. Gannon and W. Lawson, "Validating the 
Subcutaneous Model of Injectable Autologous Cartilage Using a Fibrin Glue 
Scaffold,"  Laryngoscope, vol. 114, pp. 2154-2160, 2004.  
[99] V. Prathiba and P. Gupta, "Cutaneous wound healing: Significance of proteoglycans 
in scar formation,"  Curr.  Sci., vol. 78, pp. 697, 2000.  
 
